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1Zusammenfassung
Rezeptor-Tyrosinkinasen (RTK) sind eine Gruppe von Proteinen, die in die Plasmamem-
bran eingebettet und fu¨r die Zell-Signalisierung verantwortlich sind. Im Menschen
umfassen RTK 59 Gene,die in 20 Familien eingeteilt werden. Dazu geho¨rt die Fam-
ilie der Epidermalen-Wachstumsfaktor-Rezeptoren (ErbB oder HER), die wiederum
aus vier Mitgliedern besteht: EGFR/ErbB1/HER1, ErbB2/HER2/Neu, ErbB3/HER3
und ErbB4/HER4. Diese binden unterschiedliche Liganden und bilden eine Reihe
von Homo- und Heterodimeren um verschiedene zellula¨re Antworten hervorzurufen.
ErbB-Rezeptoren sind verantwortlich dafu¨r, Signalisierung durch Liganden-induzierte
Dimerisierung auszulo¨sen und sind in Signalnetzwerke involviert, die mit Zellwachstum
und Zelldifferenzierung in Verbindung gebracht werden. Viele Mutationen der ErbB-
Rezeptoren fu¨hren zu Zelltransformation und Krebs .
Obwohl vieles u¨ber die Struktur und Aktivierung der ErbB-Rezeptoren bekannt
ist, fehlt ein komplettes Bild der molekularen Mechanismen, die zu einer Umwandlung
extrazellula¨rer in intrazellula¨re Signale fu¨hren (der Aktivierung der Kinase-Doma¨nen).
Ein Teil der ErbB-Rezeptoren in der Plasmamembran ko¨nnen bei Abwesenheit von
Liganden die Form von vorgeformten, nicht-kovalent verbundenen Dimeren annehmen.
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Im Fall von EGFR bindet der Rezeptor in vivo Liganden mit zwei Affinita¨ten. Bei einer
Aufreinigung des Rezeptors bleibt allerdings nur die Komponente mit niedriger Affinita¨t
u¨brig. Es wird vermutet, dass die hohe Affinita¨tsbindung und die vorgeformten Dimere
in einem Zusammenhang stehen und eine Art negative Kooperativita¨t aufweisen.
Aus diesem Grund entwickelte ich eine Methode, die es erlaubt, die strukturelle sowie
biochemische Charakterisierung der vorgeformten EGFR-Homodimere durchzufu¨hren.
Die Schwierigkeit lag darin, ein Werkzeug einzufu¨hren, das die Reinigung der vorge-
formten Dimere ermo¨glicht, ohne auf die Zusetzung kovalenter Modifikationen zuru¨ckgreifen
zu mu¨ssen, welche die inha¨rente Flexibilita¨t und Struktur der Rezeptoren verhindern.
In dieser Arbeit wird eine Methode vorgestellt, die es erlaubt, die EGF-Rezeptoren
bei Abwesenheit der Liganden in einem dimerisierten Zustand wa¨hrend des Reini-
gungsprozesses zu erhalten. Dieses Werkzeug besteht aus einem de novo konstruierten
heterodimerischen ”coiled-coil” (Doppelwenden), das E3/K3 genannt wird. Dieses Paar
wurde bereits beschrieben, jedoch noch nicht zu einem Protein fusioniert. Aus diesem
Grund testete ich das Verhalten des E3/K3 Paares mit Hilfe der fluoreszierenden Pro-
teinen Venus und ECFP. Durch die Verwendung von Affinita¨tsreinigungs- und Gelfil-
trationstechniken sowie von FRET zeige ich, dass das E3/K3 Paar sehr gut fu¨r die
Heterodimerisierung zweier Proteine geeignet ist. Es ist außerordentlich spezifisch und
die Interaktion ha¨lt dem Reinigungsprozess stand.
Anschließend wurde das E3/K3 Dimerisierungsmodul in EGF-Rezeptoren trans-
plantiert und in CHO-Zellen exprimiert. Die Ergebnisse zeigen, dass EGFR auch bei
Abwesenheit des Liganden in dimerischer Form gereinigt werden und weiterhin in vitro
Liganden binden kann, ohne Tyrosinkinase-Aktivita¨t zu verlieren. Außerdem ist die
Probe extrem rein und es kann fu¨r strukturelle Studien mit Single-Particle-Negative-
Staining benutzt werden. Ich stelle eine dreidimensionale Rekonstruktion eines vorge-
formten EGFR Homodimers vor wobei (soweit bekannt) zum ersten Mal eine in der
2
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vollen La¨nge RTK gezeigt werden kann. U¨berraschenderweise zeigt der vorgeformte
EGFR Dimer Ektodoma¨nenasymmetrie. Eine der Ektodoma¨nen scheint eine ”teth-
ered” (angebundene) Konfiguration aufzuweisen, wa¨hrend sich die andere in einem
freieren Zustand befindet. Da die Anwesenheit struktureller Heterogenita¨t in den Ek-
todoma¨nen auf die Mo¨glichkeit zweier verschiedener Bindungsstellen deutet, fu¨hrte ich
Ligandenbindung-Assays mit den gereinigten EGFR Dimeren durch. Das Scatchard-
Diagramm zeigt eine kurviliniare, konkave Form, die charakteristisch fu¨r in vivo EGFR-
Ligandenbindung ist. Es ist daher wahrscheinlich, dass die Ektodoma¨nenasymmetrie
direkt in Heterogenita¨t der Bindungsstellen u¨bersetzt wird, was wiederum die zwei
Affinita¨ten generiert, die in vivo zu sehen sind. Das ist das erste Mal, dass ein solches
Scatchard-Diagramm mit gereinigten EGF-Rezeptoren vorgestellt wird. In dieser Ar-
beit zeige ich eine unerwartete Architektur des vorgeformten EGFR Dimers. Anstatt
symmetrische Dimer zu formen, gehen die Ektodoma¨nen vor der Ligandenbindung in
asymmetrischer Weise zusammen. Wir hoffen, dass sich diese Entdeckung als nu¨tzlich
fu¨r die zuku¨nftige Entwicklung von Medikamenten bei der Krebsbehandlung zeigt sowie
Aufschluss u¨ber die allgemeinen Mechanismen der Signaltransduktion –nicht nur von
ErbB, sonder auch von anderen Rezeptoren – geben kann.
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2Abstract
Receptor tyrosine kinases (RTKs) are a family of plasma-membrane embedded proteins
that mediate cellular signalling. In humans, RTKs comprise 59 genes divided into 20
families. One of these is the family of the epidermal growth factor receptors (ErbBs or
HERs), composed of four members: EGFR/ErbB1/HER1, ErbB2/HER2/Neu, ErbB3/
HER3 and ErbB4/HER4. They can bind different ligands and form a wide array of
homo- and heterodimers, thus generating different cellular responses. ErbB receptors
are thought to trigger signalling by ligand-mediated dimerization, and are involved
in pathways related to cellular growth and differentiation. Many mutations of ErbB
receptors are known, and these typically lead to cell transformation and cancer.
Even though much is known about the structure and activation of ErbB receptors,
we are still missing a complete picture of the molecular mechanisms that lead to the
conversion of an extracellular signal into an intracellular event (the activation of the
kinase domains). For example, ErbB receptors are known to exist as preformed, non-
covalently linked dimers at the plasma membrane in the absence of ligand, but this
association dissapears when the receptors are purified. EGFR is also known to bind
ligand with two apparent affinities, but only in vivo. Once the receptor is purified,
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only the low affinity component remains. The high affinity binding and the preformed
dimers are thought to be related. These could present negative cooperativity that would
explain the presence of two affinity sites. For this reason, I wanted to develop a method
that allows both the structural and biochemical characterization of preformed EGFR
homodimers. The challenge was to introduce a tool that allows the purification of a
preformed dimer without the necessity of adding any covalent modifications, that would
hinder the inherent flexibility and structure of the receptor.
In this work, I have introduced a heterodimerization tool that maintains the EGF
receptors in a dimerized state in the absence of ligand throughout the purification
procedure. This tool consists of a de novo designed heterodimeric coiled-coil, termed
E3/K3. This pair has been previously described, but never fused to a protein. For
this reason, I have tested the behaviour of the E3/K3 pair when fused to two model
proteins, Venus and ECFP. By using affinity tag purification, gel filtration, isothermal
titration calorimetry (ITC) as well as FRET, I have showed that the E3/K3 pair is very
well suited for the heterodimerization of two proteins. It is extremely specific, and the
interaction is able to withstand the purification procedure.
The E3/K3 dimerization module was then transplanted to EGF receptors, and ex-
pressed in CHO cells. The results show that EGFR can be purified in the absence of
ligand in a dimeric form, and still bind ligand and possess kinase activity. Besides, the
sample is extremely clean and can be readily used for structural studies using single-
particle negative staining. I present a three-dimensional reconstruction of a preformed
EGFR homodimer, which, to our knowledge, is the first one of a near-full length RTK.
Strikingly, the EGFR preformed dimer presents ectodomain asymmetry. One of the
ectodomains seems to exist in a tethered configuration while the other appears to be in
a more extended state.
Since the presence of a structural heterogeneity in the ectodomains points to the
6
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possibility of two different binding sites, I performed ligand binding assays with the
purified EGFR dimers. The Scatchard plot shows a curvilinear, concave-up shape,
characteristic of ligand binding to EGFR in vivo. Thus, it is very probable that the
ectodomain asymmetry directly translates into a heterogeneity of binding sites, hence
generating the two affinities seen in vivo. This is the first time that such a Scatchard
plot is seen with purified EGF receptors.
With this work, I have shown that the architecture of preformed EGFR dimers
differs from what was expected. Instead of forming symmetric dimers, the ectodomains
associate in an asymmetric fashion prior to ligand binding. We hope that this discovery
will prove to be useful for the future development of anticancer drugs, as well as shed
light on the general mechanisms of signal transduction, not only of ErbBs, but also of
other receptors.
7
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3Introduction
3.1 Signalling by receptor tyrosine kinases
Cells have different ways of transferring signals from the extracellular to the intracellular
spaces. One of them involves the use of receptor tyrosine kinases (RTKs). All of these
proteins share a general architecture, with ligand-binding ectodomains, a single-pass
transmembrane helix, and an intracellular region comprising a kinase domain and a
regulatory C-terminal tail [1]. RTKs are evolutionary well conserved, from C. elegans
to humans [1, 2]. In the latter, the genome has 59 genes that encode 20 families of
RTKs [3]. They regulate key processes in the cells, related to survival, migration,
growth and differentiation, and cell cycle control [4]. Since they control very important
cellular pathways, it seems obvious that an aberrant signalling by RTKs can lead to
different pathologies, including cancer and inflammation, among others [1]. The general
mechanism of RTK activation involves ligand-mediated dimerization of the extracellular
domains and a subsequent activation of the intracellular kinase domains. However,
there are different ways of achieving activation. Some RTKs exist as covalently bound,
inactive dimers in the plasma membrane, such as the insulin receptors [5]. In some other
9
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cases, like epidermal growth factor receptors (ErbBs), a fraction of them can exist as
preformed dimers in the absence of ligand, although their function is still not clear [6].
Ephrin receptors (Eph), on the other hand, need to form higher-order oligomers to get
activated [7]. Ligand binding can also differ among RTKs. The most common case
is the cross-linking of the ectodomains by a bivalent ligand, like in the Flt1 vascular
endothelial growth factor receptor (VEGF) [8]. For some other receptors, like ErbBs,
the dimerization interface is entirely mediated by receptor contacts [6]. In any case,
and in normal conditions, the ligand binding event is necessary in all RTKs in order
to generate a cellular response. This will be started by the docking of several proteins
to phosphorylated residues in the intracellular kinase and C-terminal domains of the
RTKs. In this work, we have focused on the structural determination of a preformed
epidermal growth factor receptor dimer. We hope that this work will shed light on the
molecular mechanisms that link an extracellular binding event to intracellular kinase
activation.
3.2 The ErbB family of receptors
The epidermal growth factor receptor (EGFR) is one of the most studied protein tyro-
sine kinases, since its first sequencing and detailed description in 1984 [9]. Since then,
other three members of this family have been described in mammals, and collectively
this family of receptors are termed ErbB from their sequence similarity to the viral
erythroblastoma protein [10] or HER receptors (from Human Epidermal growth fac-
tor Receptors). They have homologs in many other organisms such as Caenorhabditis
elegans [11] and Drosophila melanogaster [12]. In the case of mammals, the four mem-
bers of the ErbB family are ErbB1/EGFR/HER1, ErbB2/HER2, ErbB3/HER3 and
ErbB4/HER4, and have 60-75% sequence identity [13].
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All members of the ErbB family are single-pass transmembrane receptors and share
a common architecture: a glycosylated ectodomain with four subdomains (∼620 aa), a
single-pass transmembrane domain, a juxtamembrane domain (∼45 aa), an intracellular
tyrosine kinase domain (∼270 aa) and a regulatory C-terminal tail (∼230 aa) [6, 14, 15]
(Figure 1).
Figure 1: General architecture of ErbB receptors. ErbB receptors have a molec-
ular weight of about 180 kDa and are composed of an extracellular, ligand binding
domain, a transmembrane domain, a juxtamembrane domain, a protein tyrosine kinase
domain and a regulatory C-terminal tail.
ErbB receptors have a molecular weight of about 180 kDa and are heavily glycosy-
lated [15]. Up to 30 kDa of the total molecular weight is represented by oligosaccharide
moieties. These sugars have proved to be crucial for ErbB action, and are especially
well characterized for EGFR [16–21]. The EGFR immature protein is 1210 aminoacids
11
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long, and will be cleaved upon plasma membrane insertion to generate the mature,
glycosylated form consisting of 1186 residues [9]. This mechanism is common to the
other ErbB members.
The ectodomain of the ErbB receptors can be subdivided into four subdomains,
classically called L1 (leucine-rich), CR1 (cystein-rich), L2 and CR2, or alternatively,
subdomains I to IV. Domains I and III are responsible for ligand binding, and domain
II contains a loop that allows dimerization of the ectodomains [1, 22, 23]. Domain IV
is thought to be involved in the maintenance of the undimerized configuration [24–26].
In normal conditions, ErbB receptors become activated after ligand-mediated dimer-
ization. The ligand-mediated dimerization and activation of ErbB receptors causes the
phosphorylation of several residues in the intracellular domains, including tyrosines,
threonines and serines (Table 3.1, adapted from [15, 27]). These phosphorylated sites,
in turn, serve as docking points for several intracellular proteins, and hence mediate
different signaling pathways [2, 28–31]. Although several residues are known to be
transphosphorylated by the kinase domains themselves, some others, especially in vivo,
can be modified by cellular proteins [32–34] like Src and Jak-2 [35, 36].
EGFR family members can form homo- and heterodimers [37, 38]. They are able
to dimerize after two molecules of ligand have bound the receptors, hence generating a
2:2 complex [14, 32, 39–45]. Hence, the ligands do not contribute to the dimerization
interface, as in other RTKs [1]. Every ErbB receptor, except ErbB2, is able to bind
different ligands (Table 3.2, taken from [15]), and if more than one ErbB receptor is
expressed in the cell, a wide array of homo- and heterodimers are formed [6]. All ErbB
receptor ligands are soluble and small (about 6-10 kDa) [15]. They are synthesised as
large, transmembrane precursors that will be cleaved to yield a mature growth factor
by ADAM metalloproteases at the plasma membrane [46].
12
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EGFR ErbB2 ErbB3 ErbB4
Phospho-Y Domain Phospho-Y Domain Phospho-Y Domain Phospho-Y Domain
703 Kinase 663 JM 661 JM 708 Kinase
740 Kinase 713 Kinase 770 Kinase 782 Kinase
777 Kinase 750 Kinase 804 Kinase 808 Kinase
789 Kinase 759 Kinase 805 Kinase 850 Kinase
803 Kinase 781 Kinase 849 Kinase 883 Kinase
845 Kinase 813 Kinase 869 Kinase 896 Kinase
867 Kinase 854 Kinase 878 Kinase 925 Kinase
876 Kinase 884 Kinase 893 Kinase 959 C-tail
891 Kinase 901 Kinase 922 Kinase 997 C-tail
920 Kinase 930 Kinase 956 C-tail 1010 C-tail
954 C-tail 983 C-tail 1035 C-tail 1031 C-tail
974 C-tail 1001 C-tail 1113 C-tail 1041 C-tail
992 C-tail 1090 C-tail 1140 C-tail 1056 C-tail
1045 C-tail 1105 C-tail 1178 C-tail 1103 C-tail
1068 C-tail 1117 C-tail 1180 C-tail 1125 C-tail
1086 C-tail 1174 C-tail 1203 C-tail 1137 C-tail
1101 C-tail 1199 C-tail 1205 C-tail 1163 C-tail
1114 C-tail 1200 C-tail 1241 C-tail 1177 C-tail
1148 C-tail 1226 C-tail 1243 C-tail 1183 C-tail
1173 C-tail 1257 C-tail 1196 C-tail
1270 C-tail 1217 C-tail
1288 C-tail 1233 C-tail
1309 C-tail 1237 C-tail
1241 C-tail
1243 C-tail
1259 C-tail
1276 C-tail
Table 3.1: Phosphotyrosine profile of ErbB receptors. Listed are residues that
get phosphorylated upon activation. Residues in red denote tyrosines that are identical
in all receptors or whose surrounding sequence is identical to other ErbB receptors. JM,
juxtamembrane domain. Adapted from [27].
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Ligand Receptor
EGFR ErbB2 ErbB3 ErbB4
EGF + - - -
TGF-α + - - -
HB-EGF + - - +
Amphiregulin + - - -
Betacellulin + - - +
Epigen + - - -
Epiregulin + - - +
Neuregulin-1 - - + +
Neuregulin-2 - - + +
Neuregulin-3 - - - +
Neuregulin-4 - - - +
Table 3.2: Ligand specificity of ErbB receptors (taken from [15]).
In the last years, extensive structural analyses have shown how the ErbB ectodomains
and kinase domains are organized. Crystal structures have revealed that when unbound,
all ErbB receptors, except ErbB2, have a tethered, closed conformation [24–26, 47–49].
Upon ligand binding, the conformation changes to an extended one and allows ligand-
mediated dimerization [23, 50, 51] (Figure 2). This event is thought to promote the
association of the intracellular kinase domains that results in their activation via an
asymmetric dimer [52]. The mechanism will be discussed extensively in section 3.3.2.
It seems clear that EGFR and ErbB4 are able to form homodimers upon ligand
binding [53], and that ErbB2 is the preferred partner for heterodimerization [48, 54–
56]. On the other hand, ErbB3 and ErbB2 are not able to homodimerize [40, 57].
ErbB3 is able to bind ligand and adopt an extended conformation in solution but
without forming homodimers, in contrast to EGFR soluble ectodomains [58]. The only
ErbB family member without a known ligand is ErbB2 [32, 40, 48]. ErbB2 adopts
a constitutively extended configuration [47, 48] that makes domains I and III to be
very close to each other, so that there is no space for a ligand molecule to bind. For
14
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Figure 2: Conformations of tethered and extended ErbB receptors. A)
Crystal structures showing the tethered, unbound conformations of EGFR, ErbB3
and ErbB4 (PDB codes 1NQL, 1M6B and 2AHX, respectively). Subdomains I to
IV have been depicted in different colours. B) Crystal structures showing the extended,
dimerization-prone configurations of EGFR bound to its ligand EGF and ErbB2 (PDB
codes, 3NJP and 1N8Z, respectively). Note that the distance between domains I and
III of ErbB2 is too small as for a ligand to bind.
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this reason, it is thought to be the preferred heterodimerization partner, since it is
poised to interact with other ErbB receptors. This is also confirmed by the fact that
overexpression of ErbB2, but not EGFR, induces cell transformation, as is the case for a
class of breast cancers [40, 59, 60]. Surprisingly, the Drosophila unbound EGFR adopts
the same extended conformation as the human ErbB2, and so a different regulatory
mechanism is involved in its autoinhibition [61].
ErbB3 is a kinase-defective receptor [40, 62, 63], and although it has recently been
described to possess a measurable kinase activity, in comparison to other receptors it
is very low [64]. For this reason, ErbB3 needs to hetero-associate with another ErbB
member in order to generate an active dimer [40, 57]. ErbB2/ErbB3 heterodimers are
the most potent signaling pair of all possible ErbB receptor dimers, due to its decreased
downregulation [40, 65–67].
Several ligands can bind the same receptor. All ligands are structurally related [15,
32], and the fact that they can trigger different signaling pathways could be explained
by how ligand binding affects the angle that subdomain II forms with the rest of the
ectodomain after this event. Slightly different angles would promote homo- or het-
eroassociation, and could have an effect in the way the intracellular kinase domains
associate [6]. The dimerization and activation of the kinase domain of ErbB receptors
has also been extensively studied. The current model involves an allosteric mechanism
in which the kinases form an active asymmetric dimer after ligand binding [13, 52, 68–
72]. Since the C-terminal domains are different in each ErbB receptor, homo- and het-
erodimerization events will cause the phosphorylation of different residues and hence
generate different signaling cascades [32]. The potency and length of the signals are
tightly regulated, mainly by receptor degradation through internalization [66, 73, 74]
and recycling to the plasma membrane [74]. Since ErbB receptors can be phosphory-
lated by different molecules in vivo, the array of cellular cascades, and hence responses,
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that can be activated is very large. The main pathways that are activated by ErbB re-
ceptors are the RAS/ERK pathway, the PI3K/AKT pathway, the JAK/STAT pathway
and the PLC/PKC pathway. These are involved in proliferation responses, such as anti-
apoptosis, cell migration, survival and differentiation [2, 28–31]. A scheme depicting
the pivotal members of these pathways can be found in Figure 3.
Apart from generating a cellular response, ErbB receptors have been reported to
reach the nucleus and probably have some transcriptional activity [75, 76]. Since ErbB
receptors control many pathways related to cell growth and apoptosis inhibition, their
aberrant signalling can lead to cell transformation and cancer. They are involved in
glioma, breast, head and neck, bladder, ovary and lung cancers, as well as in renal
carcinomas [28, 77]. There are several mutations that are responsible for the anomalous
behaviour ErbB receptors. EGFR variant III (EGFRvIII) lacks most of the extracellular
domain, cannot bind ligand and exists in a constitutively active state at the plasma
membrane [10]. There are other extracellular mutations of EGFR involved in cancer
progression [78]. The kinase domain can also be mutated in different residues, or have
insertions and deletions that make it constitutively active [79]. ErbB2 is overexpressed
in several types of cancers and can be mutated in its kinase domain [40, 59, 60], and
can also be associated with an overexpression of ErbB3 [30]. Mutations in ErbB4 are
associated with melanoma [31]. For these reasons, ErbB family members are an active
field of research for anticancer drugs. These include antibodies that bind extracellular
domains of both the wild-type and the mutated receptors (like cetuximab/ErbituxTM
and Zalutumumab in the case of EGFR and trastuzumab/HerceptinTM in the case of
ErbB2 [80]), and small molecule tyrosine kinase inhibitors (TKIs). These block the
ATP binding site of the kinase domain. Several TKIs are approved for cancer therapy,
such as erlotinib/TarcevaTM and gefitinib/IressaTM [79].
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Figure 3: Cellular pathways activated by ErbB receptors. Phosphorylated
ErbB receptors can activate four different pathways. The PI3K/AKT pathway (in
blue): PI3K binds phosphorylated receptors via its SH2 domain. It induces the gen-
eration of phosphatidylinositol triphosphate (PIP3), that serves as a docking site for
AKT. AKT acts on many other substrates, such as BAD, which is downregulated, thus
inhibiting the apoptosis response. The RAS/ERK pathway (in red): phosphorylated
receptors bind Grb2 and SHC adaptors that in turn recruit SOS, a GDP/GTP ex-
changer. GTP is then loaded on RAS, and a kinase cascade is generated that results
in the phosphorylation of ERK and its translocation to the nucleus. The PLC/PKC
pathway (in green): phospholipase Cγ protein kinase (PLCγ) binds phosphorylated
receptors, producing diacylglycerol (DAG) and inositol triphosphate (IP3). These gen-
erate Ca2+ release, which in turn activates the protein kinase C family (PKC). The
JAK/STAT pathway (in purple): Janus kinase (JAK) and STAT (Signal Transducer
and Activator of Transcription) are able to bind phosphorylated receptors. JAK then
phosphorylates STAT, which is translocated to the nucleus. Adapted from [28, 31].
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3.3 Structure and mode of action of the EGF re-
ceptor
3.3.1 Ectodomain organization
The ectodomain of EGF receptor has been crystallized in several forms, and these
experiments have given valuable insights into the ectodomain organization and its con-
sequences for EGFR activation. The crystal structure of unliganded EGFR [26] reveal
a tethered configuration, in which domains II and IV are closely interacting via a teth-
ering loop (Figure 4). Domains I and III are too far away as for the ligand to bind them
simultaneously. This architecture has also been seen for the ectodomains of ErbB3 and
ErbB4 [24, 25]. In the case of ligand bound ectodomains, two structures lacking the
majority of domain IV were solved [23, 50] in which the dimerization loop of domain II,
that was involved in maintaining the tethered conformation in the unliganded monomer,
is now interacting with a second EGFR ectodomain. A more recent crystal structure
shows the same architecture but this time including domain IV, which also seems to
be involved in the interaction between two ectodomains but to a lesser extent than the
dimerization loop of domain II (Figure 4) [51]. In either structure, two molecules of
ligand are needed to stabilize the dimeric ectodomains (2:2 interaction), which makes
EGFR a somewhat special receptor, in which the dimer interface is not stabilized by
the ligand. Domains I and III are now close enough as to allow ligand to bind them
simultaneously. The crystal structure of the liganded ectodomains shows a symmetric
architecture with an overall symmetric heart-shape. This ectodomain arrangement has
also been seen in electron-microscopy studies [81, 82].
From these studies, the mechanism of EGFR activation seemed to be easy: the
ligand would allow the untethering of domain II, poising the dimerization loop for in-
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Figure 4: Depiction of unliganded and liganded EGFR molecules. Cartoon
showing an unliganded, inactive monomer (left) and an active, liganded dimer (right).
Ligand is depicted as a red sphere. B) Left, crystal structure of an inactive, unli-
ganded ectodomain monomer (1NQL) coloured according to the subdomain boundaries
(domains I to IV). Right, crystal structure of a liganded ectodomain dimer (3NJP)
coloured following the same scheme as for the unbound structure. Ligand (EGF) is
coloured in red.
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teraction with other receptor. However, mutation studies of the residues involved in the
tethering interaction failed to demonstrate this mechanism. In studies where soluble
ectodomains were used, disrupting the tethering arm increased the affinity towards the
ligand [83], which supports the idea of domains I and III coming in closer proximity.
Yet another prediction of this model is that, if the tethering interaction is disrupted,
the ectodomains should associate via their dimerization loops in the absence of ligand.
However, mutational studies have failed to detect any ligand-independent dimerization
of this kind [50, 84]. These effects are also observed in in vivo experiments. If the
disruption of the tethering arm caused an increased rate of ligand-independent dimer
formation and activation, this should be reflected in an increase of phosphorylation
of the kinase domains. The mutational studies have shown that this is not the case
[85, 86], although disrupting the tether increased the apparent binding affinity of EGF
receptors [85, 87]. In [87] it is suggested that low affinity receptors represent tethered
and extended configurations in a dynamic equilibrium. These and other studies on the
disruption of the tethering interactions show that there must be other control mech-
anisms that maintain EGF receptor in its inactive state [6, 58] and that control its
affinity to ligands.
3.3.2 Kinase domain structure and activation
After ligand-mediated ectodomain dimerization, the signal is transmitted along the
EGFR molecule and results in the tyrosine kinase activation and phosphorylation of
several tyrosine residues. These, in turn, will serve as recruitment points for different
adaptor proteins containing PTB and SH2 domains, among others [88]. The tyrosine
kinase domain of the EGF receptor can be divided into two subdomains, called the N-
and the C-lobes. Between these two domains the so-called activation loop can be found
(Figure 5, adapted from [89]). In the N-lobe, another important regulatory element is
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found, the αC helix (Figure 5). A conserved glutamate residue is found in this helix,
and in the active conformation it helps in the coordination of an ATP molecule with the
N-lobe [89]. This organization is common to many other tyrosine kinases [89], in which
the phosphorylation of a conserved tyrosine residue in the activation loop is necessary
for the transition from the inactive to the inactive conformations. However, in the
case of the EGF receptor, phosphorylation of this residue (Y845) does not seem to be
involved in the kinase domain activation [35, 90].
In fact, the first crystal structure reported for the EGF receptor kinase [70] showed
that it adopts an active conformation with Y845 unphosphorylated. It became clear
then that there must be an alternative mechanism that prevents the EGFR kinase to be
constitutively active. Other structures of the EGFR kinase domain in an inactive state
[71, 91] were solved. They showed an organization that closely resembles the inactive
state of Src tyrosine kinases and CDK2 (cyclin-dependent kinase 2) [92, 93]. Src kinases
are found in an inactive state when bound to their SH2 and SH3 domains, and CDK2 is
inactive when not bound to cyclins (Figure 6, adapted from [89]). The key features of
this conformation are the position of the αC helix, which is facing away from the N-lobe
and preventing the correct positioning of the conserved glutamate residue needed for the
active conformation [89]. The activation loop in the inactive conformation also forms a
short helix that helps in the stabilization of the αC helix away from the N-lobe. This
is known as the CDK/Src-like conformation. In 2006, another crystal structure showed
that the EGFR kinase in the active conformation forms an asymmetric, head-to-tail
dimer [52]. The C-lobe of the activator kinase interacts with the N-lobe of the receiver
kinase (Figure 6, adapted from [89]). This is also the mode of action for the allosteric
regulation of ErbB4 and ErbB2 kinase domains [13, 68]. Mutations that disrupt the
interaction interface, or binding to a cellular inhibitor of the EGFR kinase (the Mig6
peptide) prevent the kinases from adopting the active conformation [52, 91].
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Figure 5: Conformations of the inactive and active kinase of the EGF re-
ceptor A) Cartoon showing the configuration of the αC helix, dimerization loop and
activator-binding patch in the inactive (top panel) and active conformations (bottom
panel). B) Crystal structures showing the same elements as in A) (PDB IDs, 3GT8 for
the inactive and 2GS6 for the active conformations).
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Figure 6: Comparison between Src/CDK activation and asymmetric EGFR
kinase dimersA) Src kinases are active when not bound to SH2 and SH3 domains,
while CDKs are only active after a cyclin has bound. B) EGFR asymmetric dimer, in
which the activator kinase interacts with the receiver via the activator-binding patch.
The receiver kinase adopts the same configuration as the one seen in Src kinases and
CDKs. Adapted from [89].
However, the affinity of CDK2 and Src kinases towards their substrates is very high
compared to EGFR kinases. Besides, isolated EGFR-family kinases have a very low
basal activity and only increase their catalytic activity when the local concentration is
raised, such as by attachment to lipid vesicles [52, 94]. The dimer interface seems to be
very weak, and must be stabilized in some way. In fact, recent studies have shown that
the juxtamembrane domain is enough to generate an asymmetric dimer in vitro [89].
It is well known that the juxtamembrane portion of the EGF receptor is involved in
its proper activation [95, 96], and recent structural studies, both in EGFR and ErbB4
kinases, have shown that the C-terminal part of the juxtamembrane domain is directly
involved in the stabilization of the asymmetric dimer [63, 97, 98].
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Figure 7: Activation of the EGF receptor kinase domains A) Depiction of an
inactive, symmetric dimer (left panel). The kinase domains interact via their N-lobes
(PDB 3GT8). Right panel, depiction of an active, asymmetric EGF receptor kinase
dimer including the full juxtamembrane domain. The activator kinase interacts with
the receiver via the C-lobe and N-lobe, respectively. The juxtamembrane domain of the
receiver kinase wraps around the activator kinase, and the N-terminal part forms a helix
(PDB 3GOP). B) A model of EGF receptor activation, showing the entire molecule.
After ligand dependent dimerization, the juxtamembrane domains of both kinases form
a coiled coil that brings them to an asymmetric, active configuration, allowing their
transphosphorylation. (Domains not to scale). Adapted from [89].
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In fact, the C-terminal tail of the activator kinase hides the juxtamembrane segment
in its inactive conformation [63, 97, 98]. The current activation model proposes that
the two juxtamembrane domains of the EGFR kinase dimer form a coiled-coil that is
stabilized by the dimerization of the transmembrane helices (Figure 7, adapted from
[89]). Although it seems clear that the transmembrane helices are able to interact
[99–103], although the interaction interface does not seem to be very well defined [51].
The association of the juxtamembrane domains would in turn stabilize the asymmetric
active conformation as opposed to the symmetric inactive one . However, in a recent
structural study of near full-length activated EGFR homodimers, the kinase domains
seem to be present in three different states: a putatively asymmetric, active dimer, a
symmetric, inactive dimer, and symmetric monomers [82]. Mutations and binding to
known tyrosine kinase inhibitors seem to change the equilibrium among these three
states. The fact that a single conformation of the ectodomains (dimerized) can be
coupled to several kinase configurations reveals a greater complexity than previously
established, and suggests another set of regulatory mechanisms.
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3.4 Ligand binding features of the EGF receptor
3.4.1 Curvilinear Scatchard plots of EGF receptors
Almost 30 years ago, ligand binding experiments of the EGF receptor in vivo revealed
a concave-up Scatchard plot [104, 105], characteristic of two-site binding or a negative
cooperativity event, and have been a subject of research ever since [85, 86, 95, 106–
109]. These experiments reveal two affinities of the EGF receptor for its ligand, a
high-affinity state with Kd = 0.01-0.1 nM, accounting for about 10% of the receptors,
and a low affinity with Kd = 1-10 nM, accounting for about 90% [110]. The affinity ratio
is thus about 100. Several models have been proposed in order to explain this behaviour,
which include the assumption that monomeric EGF receptors are responsible for the
low-affinity binding and that dimeric receptors represent the high-affinity state [45, 111],
heterogeneity in the spatial distribution of EGF receptors [112], invoking an unknown
intracellular component that would modulate the affinity of the EGF receptor toward
its ligand [87, 113] and assuming that the extended and the tethered configurations
of the extracellular domains represent the high- and low-affinity states, respectively
[23, 26, 47, 50]. However, a series of recent experiments have shown that negative
cooperativity between two EGF receptors is responsible for the apparent two affinity
sites [95, 107, 108, 114, 115]. In this model, the unliganded EGF receptors are able to
form inactive dimers (Figure 8 adapted from [107]).
The binding of a first ligand molecule (high affinity) would generate a structural
change on the second site and reduce its affinity. This model, supported by structural
data, has been shown for the Drosophila EGF receptor [116]. Negative cooperativity
is also known to modulate the affinity of the insulin receptor [5, 117, 118], and the
regulatory mechanisms of both insulin and EGF receptors are known to be strongly
related [5, 119]. In this way, the extracellular domains of the Drosophila EGF receptor
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Figure 8: Activation pathway of EGF receptors. Receptors are depicted by
indented circles and the ligand by a red triangle. A) Classical activation model, in
which unliganded receptors are in a monomeric state. Ligand binds to its receptor in a
sequential fashion. Once both sites are occupied, the receptors dimerize. B) Proposed
model of EGF receptor activation in an aggregating system. Receptors are now able to
dimerize in the absence of ligand without being activated. The binding of the ligand
to the first site generates a negative cooperativity event that reduces the affinity of the
second site (adapted from [107]).
have a symmetric organization when unbound. They form an asymmetric structure
after the first ligand binding event that allows negative cooperativity to occur (Figure
9, adapted from [116]). However, in the case of the human EGF receptor, a structure
of a preformed, unliganded receptor is still unknown, as are the precise regulatory
mechanisms that allow ligand binding heterogeneity to take place. It is important to
note, however, that the high-affinity state of EGF receptors is lost upon solubilisation
[110]. A recent study shows that EGF receptors reconstituted into proteoliposomes
present only low affinity binding [120]. In the same way, when vesicles containing EGF
receptors are isolated from cells, these are able to bind ligand only with low affinity,
even though in the cells they presented both affinities [121].
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Figure 9: Ligand binding model for Drosophila EGF receptors. Initially,
unbound receptors exist either as symmetric dimers (top left) or extended monomers
(bottom left). Binding of SpitzEGF (red ellipses) to one of the sites generates a second
site with less affinity in an asymmetric dimer (middle). The second binding event
generates a doubly liganded dimer that shows a general ectodomain asymmetry, as
opposed to the human liganded EGF receptor. Adapted from [116].
Taken together, these results suggest that the two-site affinity binding in EGF re-
ceptors is not only due to a simple negative cooperativity event caused by receptor
association, but also to an external cellular agent involved in maintaining or regulating
the high-affinity state, as was hypothesized before [87, 113].
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3.4.2 Preformed, unliganded dimers and oligomers of EGF re-
ceptor
If an allosteric mechanism were responsible for the two affinity sites seen in the EGF
receptor, we would expect that these are able to form dimers in the absence of ligand.
In fact, this observation has been made several times and with a very diverse array of
techniques in living cells [44, 76, 111, 122–131] and in purified receptors [120]. In some of
these studies, higher order oligomers are also detected. In this sense, EGF receptors are
similar to insulin receptors, with a main difference: insulin receptors form constitutive,
covalently bound dimers in the absence of ligand [5, 117, 118], while ligand-independent
dimerization of EGF receptors occurs spontaneously and in a dynamic fashion. In order
to understand the activation mechanism of the EGF receptor, a characterization of the
preformed, dimeric state is needed, since it seems to play a very important role in its
activation.
For these reasons, I decided to centre my research in developing a method that
allows the purification of unliganded EGF receptor dimers, and that can be used as
a general system to purify and characterize not only EGF receptor homodimers, but
also any other dimeric receptors or proteins, including other heterodimeric members
of the EGF receptor family. For this goal, a tool that is simple yet stable enough to
withstand a whole purification procedure is needed. The idea is to use of a dimerization
module that allows the proteins to stay in close contact during the purification process.
There are several dimerization strategies exploited by proteins, but one of the simplest
and most specific is the coiled-coil interaction. Besides, coiled-coils are one of the only
protein structures that can be rationally designed in order to modify their affinity and
behaviour, a very useful feature for the purposes of this investigation.
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3.5 Coiled-coil design
Proteins can associate using a wide range of mechanisms. One of them includes the
use of coiled-coils, and some analyses suggest that up to 10% of eukaryotic proteins
contain coiled-coil sequences [132]. Since coiled coils have a very characteristic primary
sequence, it is relatively easy to predict the areas of a protein that will adopt this
conformation. Coiled-coils have a basic unit that is repeated along their sequence,
called a heptad [133, 134], represented by the letters abcdefg. The residues occupying
the positions a and d have a hydrophobic character, and permit the association of
different coiled-coil strands following the knobs-into-holes model proposed by Crick
in 1953 [135]. All the residues in positions a and d associate, creating the so-called
hydrophobic core. The members of the coiled coil adopt an alpha helical structure
and wrap around each other, creating a higher-order supercoil. The residues of the
heptad in positions e and g are usually charged, and contribute to the specificity of the
coiled-coil association. The residues in the rest of positions are normally polar, and are
exposed to the solvent [133, 136, 137]. A scheme depicting the general architecture of
a coiled-coil, in helical wheel representation, can be seen in Figure 10.
Coiled-coils can homo- or heteroassociate, forming dimers, trimers or higher-order
oligomers, in parallel or antiparallel configurations. These structures are an active
subject of research, and have proved to be very good candidates for de novo protein
design [138–145]. Synthetic coiled-coils offer the possibility of working with rationally
designed protein structures that can be tested in vitro, and minimize the possible in-
teractions with cellular proteins. Properties like the association constant, specificity
and oligomerization state can also be controlled to some extent [141]. The number of
heptad repeats can also be modified, and so very powerful yet small dimerization tags
can be generated. In this sense, the use of such a tag would prove to be very valuable
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Figure 10: Helical view representation of a dimeric coiled-coil interaction.
The scheme shows the first heptad repeat abcdefg, that can be repeated afterwards.
Hydrophobic residues are shown in yellow, ionic ones in red and polar aminoacids in
blue. The coiled-coiled is stabilized by a continuous hydrophobic core and the specificity
is given by the interactions between the residues e and g.
in order to characterize preformed EGFR dimers, since these are known not to survive
the purification procedure, as has been commented on before. In this work, we have
chosen one of these de novo designed coiled-coil heterodimerization tags, both because
it is only 21 aminoacids long and because it seems to behave as a strict heterodimer in
solution [141, 146]. Its structure was solved by NMR ([146], PDB code 1U0I) and can
be seen in Figure 11 B.
The combination of a small tag, which would prevent any steric hindrance effects
with the tagged protein, and a high specificity for its heterodimerization partner make
this synthetic coiled-coil pair a very good option for our purposes. This pair is termed
the E3/K3 tag, and consists of two separate three-heptad repeats. E3 contains the
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Figure 11: Depiction of the E3/K3 interaction. A) Helical wheel representation
of the E3/K3 coiled-coil . B) NMR solution structure of the E3/K3 coiled-coil (PDB
code 1U0I). The backbone of the K3 peptide is shown in green, the backbone of the E3
in red. Leucines and isoleucines are depicted by yellow spheres, glutamic acids in green
and lysines in blue.
sequence (EIAALEK)3 and K3 is composed of three repeats of KIAALKE. A helical
wheel representation can be seen in Figure 11 A. In the first part of my work, I have
described the interaction when tagging soluble model proteins. In the second part, I
successfully purified EGFR preformed dimers with these two tags.
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4Results
4.1 Characterization of the E3/K3 interaction in fu-
sion proteins
Before starting with the purification procedure of EGFR, I performed different experi-
ments in order to elucidate how the heterodimeric coiled-coil pair E3/K3 behaves when
fused to a protein. As a simple yet informative method, the pair Venus/Enhanced Cyan
Fluorescent Protein (ECFP) was chosen and tagged with either E3 or K3 preceded by
a TEV cleavage site and followed by a StrepTagII and a His–tag, respectively. Several
experiments regarding the purity and stability of the E3/K3 system were performed.
In particular, I carried out FRET experiments in order to test the dimerization ability
under different conditions. Once the synthetic system was validated and described, I
continued with the purification and characterization of a more complex system as EGF
receptors are.
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4.1.1 Influence of peptide linkers and concentration in the so-
lution behaviour of the K3 and E3 chimeric proteins
It has been shown that the K3 and E3 peptides form a stable heterodimeric coiled coil
interaction, but the free monomers have a different behaviour. A fraction of free K3
peptides are present as homodimers in solution [147]. For this reason, I have used the
fluorescent variants Venus and ECFP (enhanced cyan fluorescent protein) to test the
behaviour of the E3/K3 pair when fused to a protein. Both chimeras (Venus-K3 and
ECFP-E3) were cloned into a pET-21 plasmid for E. coli expression, but the Venus
construct was preceded by a small S-tag at the N-terminus in order to increase its size
and differentiate it from the E3-tagged ECFP in SDS-PAGE analysis. In this study
I show that both the concentration and the neighbouring residues seem to affect the
behaviour in solution of K3. The endogenous sequence of the pET-21a linker preceding
the hexahistidine tag (KLAATLE) strongly resembles the heptad repeat of the K3
peptide (KIAALKE). The number of heptad repeats is crucial in the solution behaviour
of synthetic coiled coil sequences [141, 142]. The purified SVenus-K3-KLAATLE-his
behaves as a tetramer at higher concentrations, and the minimum molecular weight
species seen is a dimer (Figure 12 A). However, when the KLAATLE linker is exchanged
with a polyglycine linker (GGSG, denoted pG), the homodimerization of the fusion
protein at lower concentrations is disrupted (Figure 12 B) although this effect is still
seen as the concentration rises, just as with the KLAATLE construct. This points to
an intrinsic tendency of the K3 peptide to form homodimers, as shown in previous
studies [147]. We further investigated the role of the C-terminal linker in the solution
behaviour of K3 fusion proteins. We reasoned that if the polyglycine linker is mutated
to prolines (PPSG), an aminoacid usually found at the end of helices and in loops, the
limits of the heptad would be better defined, and hence the homodimerization of the
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Figure 12: Effect of concentration in the association state of the different pu-
rified constructs. All samples were brought to the desired concentration in a final vol-
ume of 250 µL and loaded onto a Superdex200 column. Theoretical molecular weights:
SVenus-K3-KLAATLE-His, 33.1 kDa, SVenus-TEV-K3-pG-His 33.7 kDa, SVenus-TEV-
K3-PPG-His 33.8 kDa, ECFP-TEV-E3-Strp 32 kDa. The calculated molecular weights
in kDa are noted above each elution peak. A) SVenus-K3-KLAATLE-his gel filtration
profiles of 4 mg/mL (continuous line) and 0.2 mg/mL (dashed line) loaded sample.
At higher concentrations, this construct elutes as a high order oligomer (possibly a
tetramer, continuous line). At lower concentrations, the protein forms dimers (dashed
line). B) SVenus-TEV-K3-pG-his gel filtration profiles of 4 mg/mL mg (continuous
line) and 0.2 mg/mL (dashed line) loaded sample. At higher concentrations, this con-
struct elutes as a dimer (continuous line) but the equilibrium is shifted towards a
monomeric form with lower concentrations (dashed line). C) SVenus-TEV-K3-PPSG-
his gel filtration profiles of 4 mg/mL mg (continuous line) and 0.2 mg/mL (dashed line)
loaded sample. The behaviour is similar to the polyglycine linker construct in B. D)
ECFP-TEV-E3-Strp gel filtration profiles of 4 mg/mL (dashed line) and 0.2 mg/mL
(continuous line) loaded sample. There is a light tendency towards homodimerization,
but the effect is very low.
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chimeric proteins would be disrupted. However, this construct behaved exactly as
the polyglycine fusion variant (Figure 12 C), which implies again an intrinsic homod-
imerization tendency of the K3 peptide. SDS-PAGE analysis shows unequivocally that
the change in molecular weight is not due to any contamination or association with
other bacterial proteins, but intrinsic to the fusion proteins (Figure 15). In the case
of ECFP- TEV-E3-Strp, the concentration-dependent homodimerization effect is very
low (Figure 12 D). Even though the fluorescent protein variants used here have a light
tendency to homodimerize at higher concentrations [148], the fact that the ECFP fu-
sion protein behaves as a monomer in solution, but the Venus fusions do not, rules
out the possibility of a Venus- or ECFP-driven homodimerization. Besides, the protein
concentration in the gel filtration assays is clearly below the concentrations needed for
a Venus or ECFP homodimerizing effect. However, it is important to point out that
K3 homodimerization does not hinder the formation of the E3/K3 heterodimeric coiled
coil, possibly because of the higher stability of the heterodimer versus the homodimer.
This is proven by the ability of SVenus-TEV-K3-pG-his to recruit all of the ECFP-
TEV-E3-Strp, both in gel filtration assays (Figure 13), ITC measurements (Figure 14
B) and fluorescence assays (Figure 14 C).
4.1.2 E3/K3-driven heterodimerization of the fusion proteins
and distance estimation
The tandem affinity purified species behaves strictly as a heterodimer in solution (Fig-
ure 13 A) at the concentrations tested. Figure 13 B compares the behaviour of the
monomeric fusion proteins versus the heterodimer. The analysis with SDS-PAGE and
Coomassie staining (Figure 15 D) together with the gel filtration profile and ITC mea-
surements (Figure 14 B) points to a 1:1 interaction of the E3/K3 fusion proteins.
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Figure 13: Gel filtration profile of the tandem affinity purified heterodimer.
A) SVenus-TEV-K3-pG-his and ECFP-TEV-E3-Strp cell lysates were mixed and sub-
jected to tandem affinity purification (StrepTactin after NiNTA). The behaviour of the
eluted species at different concentrations was tested by gel filtration. All the samples
were brought to the desired concentration in a final volume of 250 µL. The theoreti-
cal molecular weight of the heterodimer is 66 kDa. The calculated molecular weights
in kDa are noted above each elution peak. B) 4 mg/mL (continuous line) and 0.2
mg/mL (dashed line) were loaded in a Superdex200 column. This species elutes as a
heterodimer regardless of its concentration. C) Comparison of the monomeric SVenus-
TEV-K3-pG-his and ECFP-TEV-E3-Strp (orange line and blue line, respectively) and
the heterodimer (red line), 0.2 mg/mL each.
The free E3/K3 coiled coil has been shown to have a Kd in the range of 70 nM
and interact in a one to one fashion [141, 146, 147]. ITC measurements of the K3 and
E3 fusion proteins (SVenus-TEV-K3-pG-His and ECFP- TEV-E3-Strp) give a Kd of
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89.3±5.2 nM, (Figure 14 B) which is in good agreement with previous dissociation con-
stant determinations. In order to test the heterodimerization ability of the free tagged
monomers, purified SVenus-TEV-K3-pG-his and ECFP-TEV-E3-Strp were mixed at
equimolar concentrations (2 µM each) in 200 µL lysis buffer. The fluorescence levels
in the different channels (Venus, FRET and ECFP) were measured and compared to
those of a 2 µM solution of the tandem affinity purified heterodimer (Figure 14 C), and
the FRET efficiency and distance estimation calculated (Figure 14 D).
The results show that the fluorescence levels of the mixed monomers and the purified
heterodimer are the same, confirming that virtually all the monomeric molecules are
able to heterodimerize. The FRET efficiency (E) and distance estimation (d) are also
equal (E = 0.46±0.03 for the mixed samples and 0.45±0.03 for the tandem affinity
purified heterodimer; d = 51.3±0.5 A˚ mixed and 51.6±0.5 A˚, tandem affinity purified).
4.1.3 K3 and E3 peptides are biologically inert when expressed
in vivo
Even after a single affinity purification, the eluted samples are extremely clean (Figure
15), independently of the construct used. In the case of the heterodimer tandem affinity
purification, the sample is >99% pure as judged by Coomassie staining (Figure 15 D).
The fusion proteins were purified from a whole bacterial lysate, and hence were
exposed to all the proteins and peptides present in E. coli. The fact that the eluted
samples are clean of any contaminants shows that the K3 and E3 peptides are inert
in terms of heterologous association with other proteins. As demonstrated with the
tandem affinity purification of the heterodimer, they only associate with their designed
partner. These features are of extreme usefulness if the E3/K3 system is to be imple-
mented as a general affinity purification method.
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Figure 14: Heterodimerization of SVenus-TEV-K3-pG-His and ECFP-TEV-
E3-Strp. A) Workflow for Mixed SVenus and ECFP eluates (left panel) and tandem
affinity purified samples (right panel) B) Isothermal titration calorimetry of ECFP-
TEV-E3-Strp binding to SVenus-TEV-K3- pG-His. Top figure, data from 30 injections
of 100 µM ECFP-TEV-E3-Strp into the cell containing 10 µM of SVenus-TEV-K3-
pG-His in lysis buffer at 25oC. Bottom figure, best Chi-square fit (continuous line) to
the calorimetry data (squares), analysed with MicroCal Origin software. The calcu-
lated dissociation constant is Kd = 89.3±5.2 nM. B) Equimolar amounts of the affinity
purified SVenus-TEV-K3-pG-his and ECFP-TEV-E3-Strp monomers were mixed (grey
bars) and its fluorescence compared to the affinity purified heterodimer (white bars) per
triplicate. Final concentration 2 µM of each species in 200 µL lysis buffer. Error bars
show the standard error (σ/n). C) Comparison of efficiency and distance estimation
for the mixed and tandem affinity purified samples. The similar levels of fluorescence
in B) and FRET efficiency in C) demonstrate that virtually all free monomers are able
to heterodimerize.
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Figure 15: Analysis of samples after affinity purification and gel filtration.
12% SDS-PAGE analysis of purified samples from SVenus-KLAATLE-His (A), SVenus-
TEV-K3- pG-His (B) and ECFP-TEV-E3-Strp (C), Coomassie stained, 0.5 µg per lane.
Lane 1, cell lysate. Lane 2, eluate from affinity column (HisTrap or StrepTrap). Lane
3, peak from size exclusion chromatography after affinity purification, preceded and
followed by the neighbouring fractions. The K3 and E3 peptides are inert in terms of
heterologous binding to endogenous E.coli proteins when expressed in vivo. After a
single affinity purification, all the samples are >95% pure as judged with Coomassie
staining. D) 14% SDS-PAGE analysis of tandem affinity purified TEV constructs.
Lane 1, SVenus-TEV-K3-pG-His cell lysate. Lane 2, ECFP-TEV-E3-Strp lysate. Lane
3, eluate after second affinity purification (StrepTrap). Lane 4 and neighbouring lanes,
peak from size exclusion chromatography (below the black line). If a tandem affinity
purification is performed, an extremely clean, monodisperse sample is obtained. The
two monomers are clearly seen as two bands with different apparent molecular weight
(lane 4 and neighbouring lanes)
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4.1.4 The E3/K3 interaction is stable under different buffer
conditions
In order to confirm that the fusion products still retain this stability, several conditions
for heterodimerization were tested and the FRET efficiency of the sample measured.
The estimated distance between SVenus-TEV-K3-pG-His and ECFP-TEV-E3-Strp in
lysis buffer (20 mM Tris, 150 mM NaCl, 10 mM imidazole, pH 7.5) is 51.3±0.5 A˚
(Figure 16). Estimating the distance that a given linker provides between the E3/
K3 tagged proteins can be crucial for their successful co-purification. If the proteins
are bulky and the linker too short, the K3 and E3 peptides might fail in forming a
stable coiled-coil interaction due to steric hindrance. Previous studies have shown that
the coiled-coils with similar sequences to the E3/K3 coiled-coil are stable at high salt
concentration [143]. Thus, if the E3/K3 system is to be introduced as a general tool
for protein purification, it has to be resistant to commonly used reagents and protocols,
such as detergent solubilisation and high salt washes, among others. In order to test
this, the stability of the E3/K3 coiled-coil interaction in terms of FRET efficiency and
distance estimation was measured in buffers containing high salt, detergent, glycerol
and ethanol (Figure 16). The monomers were dialysed against the chosen buffer (except
for Triton X-100, where the detergent was added to the desired final concentration)
and mixed following the same protocol explained in 4.1.2. The results indicate that
the E3/K3 coiled-coil is stable under a variety of buffer conditions, which makes it
a very interesting tool for protein purification. The FRET efficiency test is a valid
tool because the fluorescence of known amounts of the monomers in a buffer can be
measured separately. This allows the effects of buffer-dependent fluorescence variation
to be cancelled out. The small differences seen in the FRET efficiency could be due to
the conformation of the C-terminal end, comprising the TEV cleavage site, the coiled-
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coil region and the affinity tag. These could have a looser or tighter conformation
depending on the buffer used, which would translate into a modest distance change
between the monomers (Figure 16).
Figure 16: Stability of the fusion E3/K3 heterodimer under different buffer
conditions. SVenus-TEV-K3-pG-His and ECFP-TEV-E3-Strp monomers were mixed
at a final concentration of 2 µM each in different buffer conditions. The FRET effi-
ciency, measured as the donor fluorescence decrease in the presence of acceptor, was
calculated and this value used to estimate the distance between monomers. A) The
FRET efficiency seems to fluctuate slightly at pH 7.5 depending on the buffer used
(first 5 bars). This difference could be due to a differential packing of the linker and the
coiled-coil in the different buffers, leading to more compact or stretched conformations.
At pH 5, the FRET efficiency drops drastically, as compared to other buffer conditions
at pH 7.5, showing a disruption of the E3/K3 interaction. This value is similar to the
TEV cleaved mixed monomers, where no FRET occurs. B) Distance calculations show
little difference among buffers at pH 7.5 (first 5 bars). At pH 5, the disruption of the
coiled-coil interaction leads to a decrease in FRET efficiency, which in turn translates
into an increase of the distance estimation. At pH5, the distance estimation is similar
to that of the TEV cleaved monomers. Note that the estimated distance of the pH 5
and TEV cleaved samples (87.0±1.7 A˚ and 89±0.6 A˚, respectively) is very close to the
effective limits for FRET (around 100 A˚).
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Since the distance estimation is proportional to the sixth root of the inversed effi-
ciency, a moderate change in efficiency produces almost no effect in the distance esti-
mation. If the E3/K3 are cleaved by TEV treatment, the FRET signal is lost (Figure
16). A recent study has shown that the E3/K3 coiled-coil stability is pH-dependent
[147]. In this study, the free E3/K3 dimer is disrupted at pH 5. E3 forms homotrimers
and K3 stays mainly as a monomer with a small fraction of homodimers. We are able to
reproduce and monitor this disruption at pH 5 as a sharp drop in the FRET efficiency
of the mixed monomers (Figure 16). However, when this sample is subjected to size
exclusion chromatography, a single-peak elution profile is seen (Figure 17).
Figure 17: Gel filtration profile of the tandem affinity purified heterodimer
at pH 5. All samples were brought to the desired concentration in a final volume of 250
µL and loaded onto a Superdex200 column. Red line, 0.2 mg/mL of the heterodimer at
pH 5, as compared to the monomeric proteins (SVenus-Tev-K3-pG-His in orange and
CFP-TEV-E3-Strp in blue).
The elution peak corresponds roughly to the size of the monomeric proteins. The
fact that the peak is slightly above the size of monomeric SVenus-Tev-K3-pG-His could
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mean that there is still a small percentage of dimers in the sample. The absence of the
E3-homotrimers observed in previous studies is probably due to steric hindrance effects
and charge effects of the linker, coiled-coil sequence and purification tag at lower pH,
which would prevent homomeric interactions. As mentioned in [147], the pH-dependent
disruption of the interaction can be very valuable in terms of drug delivery to eukaryotic
cells, because endosomal pH lies within this range. It can also be devised as a method
for elution from an affinity column if the tagged proteins are stable at pH 5.
4.2 Purification of unliganded EGFR dimers for struc-
tural analysis
Preformed EGFR dimers are known to occur in vivo and to be involved in high-affinity
ligand binding (see sections 3.4.1 and 3.4.2). However, these dimers are only stable in
vivo, and the purification procedure, if not using chemical cross-linkers, disrupts the
interaction. For this reason, I have used the heterodimeric E3/K3 coiled-coil as a tool
to allow two EGFR receptors to stay in close contact, yet being able to retain their
flexibility. The chosen expression system are CHO-K1 TetOn cells. They don’t have
endogenous EGFR, are known to express high amounts of protein and the glycosylation
pattern is very similar to that of human proteins. Besides, the doxycycline–induced
system (pBI vector, containing a bidirectional promoter) allows us to control the timing
and level of expression.
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4.2.1 Full length EGFR unliganded dimers are degraded dur-
ing purification
Several attempts to purify the full-length EGFR dimer have been performed, since
its C-terminal tail is known to be involved in the regulation of the EGFR tyrosine
kinase activity [52, 149–152]. As a fast method to assess the co-elution of an E3/K3
induced dimeric species after the second tandem affinity purification, a test purification
using transiently transfected CHO TetOn cells and spin columns has been used. A
10-cm culture plate is transfected with the desired plasmid (either pBI containing both
full-length EGFR-E3Strp and K3pGHis; or pBI containing EGFR∆998–E3Strp and
K3pGHis), solubilised, cleared and loaded onto one of the spin columns (either NiNTA
or Strep-tactin) and a normal tandem affinity purification is performed. The analysis of
the fractions in Figure 18 shows that, while the purification of a C-terminally truncated
EGFR dimer is possible, the full-length dimers seem to be degraded in the process.
It is well known that the purification of ∆998 EGFR is feasible in different cell
lines [52, 69, 81, 97, 153] be it the kinase domain only or including the ectodomains.
However, it has been shown in the literature that EGFR tends to be degraded during
purification, even in the presence of protease inhibitors ([153] and this study). It is true
that in a recent study [120] a full length EGFR has been successfully purified by using
insect cells as an expression system. It could well be that the source of the material has
a real impact in the degradation of EGFR during purification, or that it is a matter of
the purification conditions (affinity tags, etc.). In any case, this effect was not further
analyzed and the characterization of the unliganded EGFR dimer was done by using a
∆998 truncated receptor.
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Figure 18: Comparison of EGFR∆998 and EGFR full-length homodimer
purifications. CHOTet-On cells (1x 10-cm dish) were transfected with a plasmid
coding for EGFR∆998 E3/K3 homodimer or EGFR full-length E3/K3 homodimer and
induced o/n with 1µg/mL doxycycline. Soluble cell extracts were used in a tandem-
affinity purification (NiNTA and Strep-tactin). Left panels, EGFR∆998 homodimer
purification in spin columns. 1: soluble cell extract. 2: NiNTA flowthrough (FT).
3: NiNTA elution. 4: Strp-tactin FT. 5: Strep-tactin elution. Right panels, EGFR
full-length purification in spin columns. 1: soluble cell extract. 2: Strp-tactin FT. 3:
Strp-tactin elution. 4: NiNTA FT. 5: NiNTA elution.
4.2.2 EGFR∆998 can be purified in a dimeric form in the ab-
sence of ligand
Unliganded EGFR∆998 dimers can effectively be purified from stable CHO-K1 TetOn
lines co-expressing EGFR∆998-K3-His and EGFR∆998-E3-Strp. The purification scheme
involves three steps: two affinity columns (in tandem, Strep-tactin followed by nickel
affinity) and a gel filtration column (Figure 19). The order of the affinity purifications
can be reversed, but it seems that many proteins from CHO-K1 TetOn lysates can
bind to the nickel affinity column, including some contaminants that could degrade the
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sample. Besides, EDTA cannot be added to the solubilisation buffer if a nickel affinity
column is used as a first step, which implies that metalloproteases can still be active.
Figure 19: Tandem affinity purification of EGFR∆998 dimers. A) Analysis
of the solubilisation and co-elution of EGFR∆998 E3/K3 stably expressed in CHO-
K1 TetOn cells (10 x 175 cm2 dishes). The K3 peptide is followed by a hexahistidine
tag and the E3 peptide, by a StrepTagII. The order of purification was nickel affinity
followed by Strep-tactin column. The expected molecular weight of the monomers is
118 kDa plus 20-30 kDa of glycosylation. SN, supernatant after clearing the lysate
by centrifugation. Ni FT, nickel affinity flow-through fraction. Strp FT, Strep-tactin
flow-through. B) Coomassie staining of fractions from 30 x 175 cm2 dishes. In this case
the order of purification was StrepTactin followed by NiNTA. The Strep Eluted lane
does not correspond to the elution peak in order to maximize yield.
The typical yield from 30 x 175 cm2 dishes after the second affinity purification is
in the order of 0.1-0.2 mg/mL in a volume of approximately 750 µL, depending on the
cell line that is being used. The gel filtration analysis shows that the eluted sample is
mainly composed of a peak with an approximate molecular weight of 505 kDa (Figure
20 A). The glycosylated dimer has an expected molecular weight of about 320 kDa, plus
the weight of a Triton X-100 micelle (90 kDa). The fact that the calculated molecular
weight is higher than expected could indicate that one of the molecule’s dimensions is
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higher than the other (an oblate spheroid, for example). The SDS-PAGE and western-
blot analyses don’t show any other protein bound to the sample (Figure 20 B).
Next, I wanted to test if the unliganded sample really elutes as a dimer, and if
it is able to bind ligand. For this, a tandem affinity purified sample was divided in
two fractions and either loaded onto a Superdex200 column directly or treated with a
fluorescent ligand (EGF-Rhodamine) plus ATP (Figure 20 C). After ligand addition,
there is no change in the apparent molecular weight of the sample, and the fluorescence
maximum correlates with the A280 peak. This result indicates that the original, non-
treated sample elutes as a dimer, and that it is able to bind ligand in a normal way.
These samples were analyzed with SDS-PAGE followed by silver staining. The gels
show no other bound proteins, and confirm that both the unliganded and liganded
samples behave in the same way after gel filtration (Figure 20 D). However, in both
gel filtration profiles in Figure 20 A and C, a small shoulder is seen just after the main
elution peak. This peak does not show as any contaminant in the gels (Figure 20 B
and D), and it is not able to bind ligand, because after ligand addition its apparent
molecular weight does not change (Figure 20 C). A western-blot analysis of this peak
revealed a low molecular weight band that associates with the second peak (Figure 21).
We concluded that this species is a degradation product of the receptors, although the
addition to protease inhibitors to various steps in the purification didn’t eliminate this
peak, as has been shown in the literature [153].
It must be noted though, that the second peak is not always seen. In some pu-
rifications, the protein eluted as a monodisperse peak, while in the majority the small
shoulder was detected. This behaviour seems to be related to the level of expression of
the stable cell lines. The monodisperse and shoulder peaks were always seen when the
receptors were purified from a cell line having a low expression level as compared to
another cell line, where the expression levels were higher. In this cell line, the intensity
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Figure 20: Gel filtration analysis of purified EGFR∆998 dimers. A) Su-
perdex200 profile of a tandem affinity purified EGFR∆998 dimeric sample in DDM-150
buffer. No ligand was added. B) Silver staining of the eluted fractions from A) (top
panel), anti-his tag (middle panel) and anti-strep tag (bottom panel). The elution
volume of each sample is noted above the corresponding lane. C) The eluted fraction
from the tandem affinity purification was divided in two and either loaded directly
onto a Superdex200 column (unliganded, continuous line) or treated with 20 µM EGF-
Rhodamine and 1 mM ATP prior to loading (liganded, dashed line). The fluorescence
profile of this sample was measured and plotted (fluorescence, orange line) D) The silver
staining of both gel filtration runs shows no change in the apparent molecular weight
after ligand addition.
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Figure 21: Analysis of the second peak after gel filtration. Top panel shows the
two-peak profile obtained after gel filtration of NiNTA purified EGFR∆998. Bottom
panel, samples from the gel filtration were analyzed with WB (anti strep-tag) and show
a degradation product associated with the second peak.
of the second peak was always in the same range as the first peak corresponding to the
mature dimers (Figure 22).
As a way of estimating how much protein is being produced by each cell line, the
area under the curve was calculated (Figure 22 D) and divided by the total surface
of cells used for expression in each experiment. This is a valid method of comparison
since all the cells were induced in the same conditions (80-90% confluence, 20-22 hours
of induction). The cell line in Figure 22 C seems to express higher protein levels than
the cell line in A and B. Thus, the intensity of the second peak seems to be related to
the protein expression levels. In any case, all subsequent experiments, especially those
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Figure 22: Different profiles obtained in the purification of EGFR∆998
dimers. A) Monodisperse, one peak profile obtained from a low-expression cell line.
The peak corresponds to the total protein eluted from 80 x 175 cm2 dishes. B) Shoulder
peak profile obtained from the same cell line as in A). The peak corresponds to the total
protein eluted from 20 x 175 cm2 dishes. C) Two-peak sample profile obtained from a
high-expression cell line. The peak corresponds to the total protein eluted from 30 x
500 cm2 dishes. D) The area under the curve (shadowed in orange) was calculated using
the trapezoid method, and divided by the total surface of cells used in each purification.
With these to values, a ratio curve area/cm2 cells was calculated.
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related to structure determination, were done with fractions corresponding to the first
peak (elution volume of 9.57 mL) to avoid any interference from the second peak.
4.2.3 Purification of other ErbB family dimers: EGFR/ErbB2
There are numerous studies proving that EGFR exists as preformed homodimers be-
fore ligand addition. Some other studies show that, in fact, all ErbB family members
are able to form this kind of preformed dimers [44, 76, 111, 122–131]. The E3/K3
coiled-coil system is perfectly suited to study these interactions in the absence of lig-
and. For this reason, several attempts were performed in order to purify an unliganded
EGFR/ErbB2 dimer. The constructs used consist of the C-terminally truncated ver-
sions of both receptors, because we have shown that full-length molecules are somehow
degraded during the procedure. The initial attempt followed the same protocol as for
the purification of an EGFR∆998 homodimer: transient transfection of the cells, solu-
bilisation and tandem affinity purification using spin columns (Figure 23, first panel).
This experiment revealed that, although initially EGFR coelutes with ErbB2 in the
first affinity purification (Strp-tactin, Figure 23, left panel, lane 3), there seems to be
some process that degrades EGFR (lanes 4 and 5) and prevents ErbB2 from binding to
the NiNTA column (lanes 4 and 5). We were really interested in knowing why ErbB2
was unable to bind to the column, even though it carries a his-tag.
In one study [154] ErbB2 was found to associate with Hsp90 via its kinase domain.
This is probably related to the maintenance of ErbB2 in an inactive state by prevent-
ing association of the kinase domains in the absence of ligand. If Hsp90 associates
with the kinase domain of ErbB2, it could prevent the E3/K3 interaction by steric
hindrance. In order to remove Hsp90, the cells were treated with 10µM geldanamycin,
a molecule known to bind Hsp90 and separate it from its cargo protein. In this case,
EGFR seemed to escape degradation and some ErbB2 was now able to bind the NiNTA
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Figure 23: Influence of polyglycine linkers and geldanamycin in the purifica-
tion of truncated EGFR/ErbB2 heterodimers. CHOTet-On cells (1x 10-cm dish
per experiment) were transfected with a plasmid coding for EGFR∆998/ErbB2∆1007
E3/K3 heterodimer or a version of it including a 10-residue polyglycine arm just before
the E3/K3 sequences, and induced o/n with 1µg/mL doxycycline. Soluble cell extracts
were used in a tandem-affinity purification (NiNTA and Strep-tactin) in spin columns.
1: soluble cell extract. 2: Strp-tactin FT. 3: Strp-tactin elution. 4: NiNTA FT. 5:
NiNTA elution.
column (Figure 23, second panel, lanes 3, 4 and 5). To further test the steric hindrance
hypothesis, a different construct was used for the purification of EGFR/ErbB2 dimers.
In this case, a longer polyglycine linker (10 aminoacids) was inserted between the end
of the kinase domain and the beginning of the E3/K3 peptides. EGFR also seemed to
escape degradation and the amount of eluted ErbB2 increased (Figure 23, third panel,
lane 5). A combination of both approaches (longer polyglycine arm and geldanamycin
treatment) seems to have an additive effect (Figure 23, last panel), although still the
majority of ErbB2 does not bind the NiNTA column. Although we still don’t com-
pletely understand why only some of the heterodimers co-elute, the purification of a
EGFR/ErbB2 heterodimer seems feasible. However, the amount of starting material
needed for a structural analysis would be higher. There seems to be a steric hindrance
effect that would need further investigation.
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4.3 Structural analysis of the unliganded EGFR∆998
dimer
4.3.1 Negative staining and image acquisition of purified sam-
ples
Several attempts were performed before a suitable staining method was found. Both
the ability of the stain to give a good contrast for image acquisition and the reduction
of the background were thoroughly tested (Figure 24). PTA staining was too thick, and
uranyl acetate gave positively stained samples. The best stains were uranyl formate and
Nanovan. To completely remove background, the sample was washed 5X with water
prior to staining.
The negatively stained samples seem to have a high heterogeneity. Yet the biochem-
ical analysis has proved that the samples are clean and homogeneous. The apparent
heterogeneity comes from the particle itself, and is due to a high degree of asymmetry
plus the combination of different settling positions on the grid and possibly an inherent
flexibility of the molecule. The maximum radius of the particles ranges from 22 to 25
nm, and is in very good agreement with the expected size from crystal structures. For
other receptors, such as integrins, the negatively stained samples looked very similar to
the micrographs of EGFR∆998 (Figure 25) and the resolution achieved was 30 A˚ [155].
However, for image acquisition in a 300 kV Polara, Nanovan gave a very low contrast,
and needed a very high cumulative electron dose for the particles to be seen. On the
other hand, uranyl formate gives a very good contrast at low electron doses and hence
was chosen as the stain for further analysis.
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Figure 24: Negative staining of purified EGFR∆998 dimers. A) Phospho-
tungstic acid staining (PTA). B) Uranyl acetate pH 5 staining. C) Nanovan pH 7
staining. D) Uranyl formate pH 4 staining. High tension 80 kV, magnification 71000x.
Scale bar is 500 nm.
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Figure 25: Comparison of negatively stained dimeric EGFR∆998 and inte-
grin. Left panel, EGFR∆998 stained with uranyl formate. Right panel, integrin αVβ3
complexes stained with uranyl acetate (taken from [155]). Scale bar is 100 A˚.
4.3.2 3D model of the EGFR∆998 E3/K3 dimer reveals ectodomain
asymmetry prior to ligand binding
Once a suitable negative staining method was found and image acquisition set up, single
particles were manually picked from the micrographs and extracted. A total of about
∼12000 particles were then used in an unbiased, reference-free maximum-likelihood 2D
round (ML2D) in Xmipp [156–158], and sorted into 50 different classes. Even though
the micrographs showed structural heterogeneity, the initial ML2D analysis yielded
some very well defined views that can be seen in Figure 26.
The fifty classes generated in the ML2D round were split into 150 classes that
were taken as initial references for subsequent multi-reference analysis (MRA) and
multi-statistical analysis (MSA). The results of the fourth refinement step are shown
in Figure 27. This analysis showed that the particles are able to generate distinct
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Figure 26: First 50 ML2D classes sorted by number of members per class
(from top left to bottom right) of unliganded EGFR∆998 dimers. ∼12000 particles
were manually picked from the micrographs, extracted and used in an initial reference-
free ML2D round. In spite of the apparent structural heterogeneity, the ML2D yielded
50 different classes, some of them having a very defined shape.
views of what seems to be a highly asymmetric structure, as most of the classes show
completely different shapes. Initial attempts for reconstructing a 3D model involved a
built-in algorithm, but yielded no results. For this reason, I decided to take another
approach. Since X-ray crystallography and NMR have been used to solve the structures
of the different domains of the EGFR molecule, I created an initial dimeric model of an
inactive EGFR∆998 molecule by placing all these parts together (ectodomains, PDB
code 1NQL, transmembrane domains of a EGFR/ErbB2 heterodimer PBD code 2KS1,
juxtamembrane plus kinase domains PDB code 3GOP). The model generated in this
way was a symmetric homodimer, as can be seen in Figure 28 A and B. This model
was then filtered to 25 A˚ resolution and used to generate a set of different Euler angles.
These were then visually compared to the classes from the fourth MRA/MSA round
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(Figure 27, red squares and Figure 28 C), and the Euler angles for these views assigned
(supervised classification). Surprisingly, this method was able to generate an initial 3D
reconstruction that looked similar to the modelled chimera but differed in other ways
(Figure 29).
Figure 27: Selected classes for initial 3D reconstruction. The 50 initial classes
obtained by free ML2D were used as references for subsequent rounds of MRA/MSA.
After the fourth MRA/MSA iteration, 150 classes were generated and sorted by score.
Only the top 70 are shown in this figure. Red squares denote the classes that were
manually selected for the first 3D reconstruction.
Apart from the slight size change (the PDB structures don’t contain all the sugar
chains, and the stain depositing around the molecule creates a shell that can distort
the size), the most prominent difference is the fact that, in the reconstruction, the
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Figure 28: Initial Euler angle assignment and 3D reconstruction. A) Crys-
tal structures for the EGFR tethered ectodomain (PDB code 1NQL), transmembrane
(2KS1) and kinase domains (3GOP) were manually docked to resemble an inactive,
symmetric homodimer. B) The dimeric structure showed in A) filtered to a resolution
of 25A˚. C). The filtered initial 3D reference was used to obtain projections with known
Euler angles (top panel) that were manually compared to the classes shown in Figure
27. Those with high visual correlation were selected for Euler angle assignment and ini-
tial 3D reconstruction (middle panel). Bottom panel shows reprojections of the initial
3D model after the reconstruction.
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Figure 29: First 3D model of a EGFR∆998 E3/K3 preformed dimer. The
seven selected classes in Figure 28 were used for the first reconstruction. A) Comparison
between the initial 3D model (left) and first 3D reconstruction of the EGFR∆998 E3/
K3 dimer, showing a front view. B) Different views of the reconstruction showing the
boundaries between the two ectodomains. From left to right, left, back, right and top
views (relative to the back view).
ectodomains seem to interact in an asymmetric fashion. The boundaries between
the two ectodomains are highlighted in Figure 29 B. Unfortunately, the resolution was
not enough to show the way the kinase domains interact. In any case, and since we
had an initial 3D model that could be used as a reference for subsequent analyses,
the number of particles was increased (final number ∼24000) in order to refine the 3D
reconstruction. The single particles were then matched to the references using an Euler
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angle increment of 4o.
The increase in the number of particles and their subsequent analysis improved the
resolution of the 3D reconstruction, as can be seen in Figure 30. The final resolution
achieved is about 33 A˚, and the Euler angle plot shows that many different views were
covered (Figure 31). The most striking feature of this model is that, as seen with the
initial 3D in Figure 29, the ectodomains interact in a highly asymmetric way. The left
ectodomain (with respect to the back view) closely resembles the tethered monomer
seen in X-ray crystallography structures, although domains III and IV seem to form a
90o angle with domain II (Figure 30, back view, bottom right panel). In this respect,
the junction between domain II and domain III appears to be quite flexible. The right
ectodomain, on the other hand, seems to adopt an extended conformation (Figure
30, front and right views, top left and bottom right panels, respectively). This semi-
extended configuration of the ectodomain has been seen in other studies [159], although
as part of a monomeric receptor. In this publication, the extracellular domain seems
to flap back and forth from the tethered to the semi-extended configuration.
The difference between the conformation of the ectodomains can clearly be appre-
ciated in Figure 32, where the final 3D map was segmented and coloured according to
density boundaries (built-in function in Chimera). In this way, domain IV of the left
ectodomain (blue) wraps around and behind the right ectodomain (orange). The in-
teraction interface between the ectodomains appears to span from domain I to domain
IV of the left monomer (blue) and domain II to domain IV of the right monomer. The
closest interactions seem to be between domains I-II of the left monomer and domains
II-III of the right one, and both domains IV. However, the resolution does not allow us
to show a more detailed view of what these interactions are.
With respect to the transmembrane, juxtamembrane and kinase domains, we found
the same limitation. The resolution is enough to say that both kinase domains fit into
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Figure 30: Final 3D reconstruction filtered to 25 A˚. After several rounds of
automated single-particle projection matching in Imagic, a final 3D structure of the
whole molecule was reconstructed and filtered to 25A˚. The model presents an unmis-
takable ectodomain asymmetry, as can be appreciated in the different views. The kinase
domains are also clearly defined. Scale bar is 250 A˚.
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Figure 31: Euler angle coverage and resolution of the final 3D reconstruction.
A) Euler angle coverage (gamma versus beta). Thicker dots indicate a larger number
of particles per angle pair. B) FSC half bit threshold (blue line) and FSC curve of the
last 3D reconstruction. The two curves cross at a 1/resolution of 0.03, or about 33 A˚
resolution.
the 3D map, but we cannot tell in which configuration. We think, however, that the
spike-like feature protruding from the kinases is indeed the E3/K3 coiled-coil. In any
case, a map with higher resolution is needed in order to have a more detailed view of
the way the kinase domains interact in an inactive dimer.
For this reason, only the crystal structures of the extracellular domains were used
for docking into the electron density map. They fit extremely well into the ectodomain,
as can be seen in Figure 33, especially into the left one. However, as it was mentioned
before, the junction between domain II and III forms a different angle as the one seen
in the crystal structure. This new angle allows the domain IV of the left ectodomain to
wrap around and behind the right one, and form an extensive interaction interface. In
the case of the right ectodomain, it seems to adopt a semi-extended configuration, as
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Figure 32: Contoured ectodomains of the final 3D reconstruction. The final
3D map was segmented with Chimera, and those segments corresponding to the two
ectodomains were fused and coloured (initial number of segments per ectodomain was
2). Left domain, blue. Right domain, orange.
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mentioned above. This can be shown by the docking of the crystal structures in Figure
33.
The crystal docking shows that the left ectodomain is in a tethered conformation,
very similar to the one found in the crystal structure 1NQL. However, and as mentioned
before, the different domains seem to exist in a more relaxed state. This is especially
true for domain IV, which appears to form a different angle with the rest of the molecule.
In the crystal structure, domain IV is aligned with domains I, II and III, whereas in the
electron density map domain IV forms an angle of about 90o (Figure 33, back view).
This domain also seems to closely interact with domain IV of the right monomer. The
3D model also shows that the boundary between domain IV and transmembrane domain
of the left monomer (blue) forms a strong angle. In this sense, our structure differs from
the proposed models in that the transition between these two domains is not smooth
and linear, but rather very flexible. Although the resolution achieved in the final 3D
model doesn’t allow us to clearly identify the exact contacts between the ectodomains,
we can say that they interact in an extensive manner and asymmetrically. The whole
ectodomain of the left, constrained monomer seems to be involved, whereas for the
right, extended one, only domains II, III and IV appear to interact with the tethered
ectodomain.
Since the right domain seems to adopt an extended configuration but it doesn’t
appear too defined in the final 3D model, we wanted to test if this ectodomain is actually
scanning different conformations. This would imply that what we see is actually an
average of all these. For this purpose, a maximum-likelihood 3D (ML3D) run was done
in Xmipp [160], using as a starting model the final 3D reconstruction shown in Figure
30. Three different ML3D structures were generated, of which two of them are shown
in Figure 34.
The results of the ML3D show that the right ectodomain is able to adopt different
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Figure 33: Crystal docking of EGFR ectodomains (1NQL) into the
ectodomain electron density maps. The PDB file was divided into two parts:
domains I-III and domain IV. The left, tethered ectodomain is shown in shades of blue.
The right, extended one, in shades of orange. It is very easy to see that if domain
IV pushes domain III forward in the right ectodomain (orange), this will be closer to
domain I, creating a high affinity site.
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Figure 34: ML3D results of the final 3D model. Panels show front (top left),
left (top right), back (bottom left) and right views (bottom left). The area of the right
ectodomain that shows the highest difference in density in the two maps is marked with
black arrows.
configurations, while the left one only shows minor changes. In this respect, the most
prominent change comes from domains II, III and IV of the right ectodomain. In one of
the structures, these seem to make extensive contacts with the left ectodomain, while
in the other the interface between the two ectodomains seems to be reduced to contacts
through domain III of the right monomer and domain I of the left one (Figure 34, black
arrows). In the ML3D 1 structure, the right ectodomain seems to be pushed forward,
while in structure 2 it interacts more closely with domain IV of the left ectodomain.
Unfortunately, and as was the case with the final 3D reconstruction, the resolution is
not enough to see changes in the kinase domains. For clarity reasons, the maps were
contoured and coloured according to their volume density and are shown in Figure 35.
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Figure 35: Contoured ectodomains of the two ML3D maps. The most promi-
nent difference between the two structures can be seen in the right ectodomain (orange).
4.3.3 Binding of EGF induces large structural re-arrangements
in EGFR∆998 E3/K3 dimers
From the biochemical analysis, we know that the E3/K3 induced dimer is able to bind
ligand (Figure 19). We wanted to test if ligand binding had an effect in the structure
of an EGFR∆998 E3/K3 dimer. For this purpose, after a tandem affinity purification,
the samples were treated on ice with 20 µM EGF for 15 minutes and 0.1 mM ATP
for 15 minutes. Afterwards, the sample was loaded onto a Superdex200 column. The
negative staining and image acquisition were done following the same protocol as for the
unliganded EGFR E3/K3 dimers. About 12000 particles were manually picked from
the micrographs and an initial, reference-free ML2D performed in Xmipp [156–158]. As
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with the unliganded dimer, the initial characterization showed several classes with a
defined shape, and different from the unliganded dimers, which are shown in Figure 36.
Figure 36: First 50 ML2D classes of liganded EGFR∆998 E3/K3, sorted by
number of members per class (from top left to bottom right). ∼12000 particles were
manually picked from the micrographs, extracted and used in an initial reference-free
ML2D round.
Some of the classes (especially 1, 2 and 3) show a very distinctive view of the
activated EGFR dimer, as has been published before [81, 82]. The structural change
from unliganded to liganded dimers is also obvious, as compared to Figure 26. Not
only are the unliganded EGFR E3/K3 dimers able to bind ligand, but also this event
triggers a major conformational change in the ectodomains as has been described in the
literature [81, 82]. After the initial ML2D round, the classes were imported to Imagic
and used as references for subsequent rounds of MRA/MSA, following the same protocol
as for the unliganded dimers. The results of the third MRA/MSA round showing the
top 70 classes (of a total of 200 classes) are presented in Figure 37.
Some of the classes show the distinctive view of a liganded EGFR dimer, as was the
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Figure 37: Top 70 classes of liganded EGFR E3/K3 dimers. The 50 initial
classes obtained by free ML2D were used as references for subsequent rounds of MRA/
MSA. After the third MRA/MSA iteration, 200 classes were generated and sorted by
score. Only the top 70 are shown in this figure.
case for the initial ML2D round. However, and even though the ectodomains seem to
be very defined, the kinase domains appear as a blur in most of the cases. It also seems
that the number of views is somewhat reduced as compared to the unliganded dimers,
possibly because of a different interaction with the carbon grid after ligand binding.
A 3D reconstruction of a liganded EGFR dimer was not possible, even though several
approaches were tried. Contouring the classes and even trying to process the kinases and
ectodomains separately yielded no results. This is probably because the kinase, once the
dimer is active, becomes extremely flexible and mobile. Hence, the ectodomains appear
very well defined, while the kinase domains do not. A different approach is needed in
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order to obtain the structure of a liganded dimer, possibly involving reduction in the
flexibility of the kinase domains.
4.4 Biochemical characterization of dimeric EGFR∆998
4.4.1 Unliganded EGFR∆998 dimers are able to phosphory-
late and trigger downstream signalling upon ligand bind-
ing
Different experiments were performed to check if the E3/K3-induced EGFR∆998 ho-
modimers were able to behave as the wild type receptor. This includes plasma mem-
brane localization and activation and signalling upon ligand binding. To check the lo-
calization of the preformed dimers, CHO-TetOn cells stably expressing EGFR∆998 E3/
K3 homodimers were treated with EGF-Rhodamine (50 ng/mL) on ice after overnight
expression and serum starvation. For the initial localization of the receptors, cells were
immediately methanol-fixed after EGF-Rhodamine treatment and washing (Figure 38,
left panels). The ability of the receptors to be internalized after ligand binding was
tested by placing the EGF-Rhodamine treated cells at 37oC for 15 minutes. After
this, cells were methanol-fixed and imaged with a confocal microscope (Figure 38, right
panels).
Preformed EGFR∆998 E3/K3 dimers are correctly localized at the plasma mem-
brane, and become internalized upon ligand binding, as can be clearly seen in Figure
38. Next, I wanted to test if the preformed dimers are also able to retain their phospho-
rylation activity and trigger signalling after ligand binding. For this experiment, cells
expressing EGFR∆998 E3/K3 dimers were induced and starved overnight, and treated
with or without EGF (100 ng/mL) on the next day. After this treatment, cells were
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Figure 38: EGFR∆998 E3/K3 are present at the plasma membrane and
internalized upon ligand binding. CHO TetOn cells stably expressing EGFR∆998
E3/K3 dimers were treated with 50 ng/mL EGF-Rhodamine on ice and either methanol-
fixed and imaged directly (left panels) or transferred to 37oC for 15 minutes before
fixation and imaging (right panels). Scale bar is 20 µm.
directly lysed in 700 µL of 2.5X Laemli buffer supplemented with 1 mM Na3VO4. These
lysates were then used to probe the phosphorylation state of the cells. As a positive
control, A431 cells were used (A431 cells overexpress EGFR receptors) (Figure 39).
In order to rule out the possibility that the increase in phosphotyrosines comes from
the overexpression of one of the monomers, an ECL quantification of the anti-His and
anti-Strep signals was made. Since we know that the purified molecules elute as a
dimer, the ratio between the anti-His and anti-Strep signals of an affinity-purified and
gel-filtrated sample was used as reference of a 1:1 ratio. This was then compared to the
signal ratio of the anti-His and anti-Strep of cell lysates, and the results are shown in
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Figure 39: EGFR∆998 E3/K3 dimers are able to phosphorylate and trigger
downstream signalling upon ligand binding. Cells were seeded in 6-well plates and
left to reach 80-90% confluence. CHO TetOn cells stably expressing EGFR∆998 E3/K3
dimers and unmodified CHO TetOn cells were washed twice with PBS and expression
induced for 22h in DMEM serum-free medium containing 1 µg/mL doxycycline. A431
cells were starved in DMEM serum-free medium for the same period of time. Cells were
then treated with (+ lanes) or without (- lanes) 100 ng/mL EGF in DMEM serum-free
plus 0.1% BSA for 8 minutes at 37oC. Wells were immediately washed twice with ice
cold PBS and collected in 700 µL 2.5X Laemli buffer supplemented with 1 mM Na3VO4,
boiled for 5 minutes and analyzed by western blot. B) Western blot His/Strp ratio of
gel filtration samples versus total cell lysates. The gel filtration ratio represents a 1:1
interaction. EGFR∆998 E3 seems to be about 20% more abundant than EGFR∆998
K3 in cells, which implies that about 80% of the molecules are dimeric. This result
demonstrates that the increase in the anti-pY signal upon ligand binding comes from
the preformed dimers and not from an overexpression of one of the monomers.
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Figure 39 B. About 80% of the molecules in vivo are present as dimers, which confirms
that the increase in phosphotyrosines comes from the activation of the preformed dimers
after ligand binding. The results indicate that preformed EGFR∆998 E3/K3 dimers
are able to be phosphorylated after ligand binding, as well as to trigger downstream
signalling, as demonstrated by the anti-pErk lane. However, this truncated form of the
receptors is lacking most of the canonical autophosphorylation sites of EGFR, which
are mainly located at the C-terminal tail. Other phospho-tyrosine sites, however, are
thought to be phosphorylated by intracellular proteins upon ligand binding [33–36].
According to the literature, the truncated form of EGFR receptors used in this study
contains one tyrosine autophosphorylation site, Y992. Nevertheless, it has been recently
shown that EGFR receptors are also able to autophosphorylate at Y845 ([153] and this
study), although the phosphorylation of this site has been traditionally attributed to
Src. For this reason, we wanted to test if these sites become phosphorylated after ligand
binding (Figure 40).
The analysis of the phosphorylation state of both Y845 and Y992 of EGFR∆998 E3/
K3 in stably transfected CHO-TetOn cells revealed that, in the absence of ligand, these
sites have a very high basal phosphorylation. The levels of this basal activity are not
changed upon ligand binding (Y845) or only slightly (Y992). The analysis of A431 cells
indicates that the antibodies are working properly. However, and even though these
sites seem to be highly phosphorylated before ligand binding, downstream signalling and
overall phosphotyrosine levels remain responsive to ligand addition. This result could
indicate that, either predimerization causes the phosphorylation of Y845 and Y992, or
that some cellular proteins in CHO cells are phosphorylating these sites in the absence of
ligand. For this reason, CHO-TetOn cells were transiently transfected with full-length
monomeric EGFR and the phosphorylation state analyzed in the same way. These
results show that the basal phosphorylation of Y845 is CHO-cell dependent, as the
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Figure 40: Phosphorylation analysis of EGFR∆998 E3/K3 and full-length
EGFR reveals higher basal signals in CHO TetOn cells. Cells were seeded in
6-well plates and left to reach 80-90% confluence. CHO TetOn cells stably expressing
EGFR∆998 E3/K3 dimers and full-length EGFR transiently transfected CHO TetOn
cells were washed twice with PBS and expression induced for 22h in DMEM serum-free
medium containing 1 µg/mL doxycycline. A431 cells were starved in DMEM serum-free
medium for the same period of time. Cells were then treated with (+ lanes) or without
(- lanes) 100 ng/mL EGF in DMEM serum-free plus 0.1% BSA for 8 minutes at 37oC.
Wells were immediately washed twice with ice cold PBS and collected in 700 µL 2.5X
Laemli buffer supplemented with 1 mM Na3VO4, boiled for 5 minutes and analyzed by
western blot.
full-length EGFR is highly basally phosphorylated, and only a slight increase in pY845
is seen upon ligand binding. The same is true for Y992 and total phosphotyrosine,
although the activation levels are higher than Y845. Downstream signalling doesn’t
appear to be affected by this basal activity. Since the results were similar to those
obtained with the truncated and dimerized version of EGFR, we can conclude that
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CHO-TetOn cells, and not predimerization, induce a higher basal phosphorylation of
EGFR in our experimental model. The increase in tyrosine phosphorylation seen after
ligand binding in EGFR∆998 E3/K3 dimers is not due to Y845 or Y992. Hence, there
are two possibilities left: either EGFR receptors are able of autophosphorylating other,
as of yet undescribed tyrosines; cellular proteins recognize and phosphorylate other
tyrosines only after ligand binding; or a combination of both. It is known that several
other residues are recognized and phosphorylated by cellular proteins [33–36]. The
question is, how are these cellular proteins able to phosphorylate these tyrosines only
after ligand addition, and not before? In our model system, the EGFR kinase domains
are predimerized. The predimerization would bring the kinases to interact in a definite
way, which could hide or sterically block tyrosines that will only be phosphorylated upon
ligand binding. This event produces a structural change in the extracellular domains,
which is then transmitted to the kinase domains. This will also change the way they
interact, becoming able to be autophosphorylated and exposing the blocked tyrosines
as targets for phosphorylation.
4.4.2 Tyrosine kinase activity of purified unliganded EGFR∆998
dimers is independent of ligand addition
The phosphorylation capabilities of the EGFR∆998 E3/K3 dimers was tested in vitro.
For this experiment, two different approaches were followed: western blot analysis of the
phosphotyrosine content of in vitro activated EGFR∆998 E3/K3 dimers, and ability of
the dimers to phosphorylate an exogenous synthetic substrate. For the first approach,
EGFR∆998 E3/K3 dimers were purified and loaded onto a Superdex200 column. Frac-
tions containing the dimers were split into two, and treated either with ATP only or
with EGF and ATP, and the phosphorylation state was analyzed by western blot (total
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phosphotyrosine, pY845 and pY992) (Figure 41 B). For the second approach, a Univer-
sal Tyrosine Kinase Assay (Takara, MK410) was used. Gel filtration fractions were split
into two, and loaded onto a well of a 96-well plate coated with a synthetic poly-(Glu-
Tyr) substrate, with a wide specificity spectrum. Wells were treated with or without
20 µM EGF on ice for 20 minutes, and the reaction was started by adding 20 µM ATP.
The detection of the phosphorylated substrate was done following the addition of an
anti-phosphotyrosine antibody and colorimetric quantification (ELISA) (Figure 41 C).
Surprisingly, the phosphorylation state and the ability of the EGFR∆998 E3/K3 dimers
to phosphorylate an exogenous peptide didn’t show any change upon ligand binding,
in contrast to what happened in vivo. This means that the kinase is active in vitro
even in the absence of ligand. Since the original samples had no detectable levels of
phosphorylation (Figure 41 A) the subsequent tyrosine phosphorylation comes from the
kinases themselves. We hypothesised that the kinases are active even in the absence
of ligand because of the solubilisation from the plasma membrane. The anchoring to
the plasma membrane would prevent the kinases from adopting an active conformation
in the absence of ligand. A recent publication [120] strongly supports this hypothesis.
Purified EGFR molecules have tyrosine kinase activity in the absence of ligand, just as
we see in this study. However, when these EGFR molecules are inserted into a special
mixture of lipids, thought to resemble the composition of certain regions of the plasma
membrane, the kinase activity is only seen upon ligand binding.
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Figure 41: In vitro kinase activity of purified EGFR∆998 dimers. The eluted
fractions from a gel filtration were divided into two aliquots, and treated with ATP in
the presence or absence of EGF. A) Initial phosphorylation state of the cell lysate (SN)
and after NiNTA elution, showing that the proteins had no detectable phosphorylation
prior to the addition of ATP. B) Phosphorylation state of the eluted fractions after
ATP treatment with or without EGF. Fractions were treated with or without 20 µM
EGF for 20 minutes on ice, and the phosphorylation reaction was started by adding
ATP at a final concentration of 20 µM. The samples were at room temperature for
15 minutes, and the reaction was stopped by the addition of 1X Laemli buffer and
subsequent boiling. Above the last panel, the mL of elution of the gel filtration sample
are shown. C) Colorimetric assay showing the tyrosine kinase activity profile of the
eluted dimers in the absence (red) or presence (blue) of EGF, treated as in B). The gel
filtration profile is shown as a black line. See text for more details on the assay.
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4.4.3 EGFR∆998 dimers bind ligand with high and low affini-
ties
The ability of EGFR receptors to bind ligand with two different affinities in vivo has
been unexplained for more than two decades [86, 95, 104–109]. When EGFR is puri-
fied, the apparent two-site affinity disappears [110, 120]. It has been suggested that
preformed EGFR dimers are responsible for the high-affinity binding of EGF [45, 111],
or that the receptors achieve the high-affinity conformation by interacting with cellular
components [87, 113]. These components would be lost during the purification proce-
dure, and with them, the high-affinity binding. We wanted to test if the predimerization
of EGFR has an effect in maintaining the high-affinity binding seen in vivo. For this
reason, a ligand saturation curve experiment was performed, using europium-labelled
EGF (Eu-EGF) as ligand. Gel filtration purified samples were pooled and added to a
96-well NiNTA coated plate. Eu-EGF was added to each well at concentrations ranging
from 0.01 nM to 70 nM, per triplicate, and the time-resolved fluorescence (TRF) of the
samples was measured after the reaction reached equilibrium. Data were analyzed with
GraphPad Prism, and a comparison of fits between one-site and two-site binding was
performed. A two-site binding was preferred (P = 0.0003). Surprisingly, the purified
dimeric EGFR∆998 E3/K3 dimers still retain both high- and low affinity sites, as evi-
denced by the biphasic, concave-up Scatchard plot obtained (Figure 42), characteristic
of binding assays performed in vivo.
To our knowledge, this is the first time that purified EGF receptors are able to
reproduce the ligand binding behaviour seen in vivo. The high- and low affinity con-
stants were calculated and have values of Kd1 = 0.22 ±0.15 nM and Kd2 = 30.8 ±8.1
nM. The affinities are somewhat higher than the ones reported in the literature for in
vivo assays, but this could be due to the fact that the receptors are not in their native,
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Figure 42: Ligand saturation analysis of purified EGFR∆998 E3/K3 dimers.
Fractions containing EGFR∆998 unliganded dimers were pooled and bound to black
nickel-coated 96 well plates per triplicate. Europium-EGF (Eu-EGF) was added to the
wells at concentrations ranging from 0.01 to 70 nM. Non-specific binding was calculated
per duplicate by adding 3 µM unlabeled EGF at each concentration of Eu-EGF. Fluo-
rescence levels were measured by TRF (time resolved fluorescence) after incubation for
two hours at room temperature. A) Experimental data (red dots) were fitted to a two-
site binding curve (black). Non-specific binding is shown in blue. Kd1 = 0.22±0.15
nM. Kd2 = 30.8±8.2 nM. Percentage of high affinity sites, 0.83±0.48 B) Scatchard
transformation of the experimental data (red dots) and the fitted curve in A) (black
line). Bars denote standard error.
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membranous environment, or that the induced E3/K3 dimerization is able to mimic
the interaction only to some extent. This could also explain the fact that only a small
percentage of the molecules (about 1%) seem to retain high affinity binding. In any
case, the affinity ratio (about 150) is similar to wild type receptors.
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Ligand-mediated signal transduction via EGFR receptors has been extensively studied
in the last decades. Much is known about the regulation, activation and downstream
signalling following EGF binding, as well as about the structural features of the separate
domains of EGFR. However, we are still lacking a detailed view of how the signal
is transmitted from the extracellular medium to the cytoplasm. EGFR is known to
undergo extreme structural changes upon ligand binding, and these changes in the
ectodomain must somehow be transmitted to the kinase domains. There are many
studies showing that a very important part of EGFR signal transduction is mediated
by preformed EGFR dimers at the plasma membrane. In this study, I have described
how this dimer associates, exhibiting ectodomain asymmetry and giving a possible basis
for the high and low affinity sites observed in these receptors for more than two decades.
To our knowledge, this structure represents the first three-dimensional reconstruction
of a near full-length receptor tyrosine kinase. This was possible by the introduction of a
new purification tool, a heterodimeric coiled-coil, which allowed the preformed dimers
to resist the purification procedure.
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5.1 The E3/K3 coiled coil as a universal dimeriza-
tion and purification tool and its applications
for signal transduction studies
The E3/K3 coiled-coil interaction has been described extensively in the past, but its
components were always free peptides [141, 146, 147]. In this study I have showed how
a synthetic, de novo designed heterodimeric coiled-coil can be used as a dimerization
and purification tool, with the attachment of an affinity tag at its C-terminus. By
using FRET measurements and gel filtration assays, I have illustrated how these two
peptides perform when attached to a protein. The general behaviour is very similar
to what other studies have shown, but there are some main differences. In the case
of the E3 peptide alone, its behaviour in solution is virtually monomeric, up to the
concentrations tested. However, the K3 peptide shows a very strong dependency on
the surrounding residues, as I have demonstrated with the KLAATLE and polyglycine
experiments. This is probably due to the fact that, because of sequence similarities, the
pET21 linker behaves as a fourth heptad repeat. The number of heptad repeats has
been shown to be important for coiled-coil design [141]. In any case, and even when
followed by a polyglycine arm, the K3 peptide has an intrinsic concentration-dependent
tendency towards homodimerization. In terms of specificity, I have shown that the E3/
K3 interaction performs impeccably. Virtually all E3-tagged molecules are recruited by
the K3 peptide, and no other natural protein, from prokaryotic or eukaryotic origin,
binds any of the pair members. It also resists the most common reagents used in protein
purification. However, the pH dependency when attached to a protein seems to differ
from the behaviour observed in the free peptides [147]. The association appears to be
effectively disrupted at pH5, but instead of E3 homotrimers, the proteins seem to behave
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as monomers in solution. It is not probable that this effect is due to a specific property of
Venus and ECFP. We hypothesise that the absence of homotrimers can be explained by
both steric hindrance effects with the much bulkier tagged proteins, and the dependence
on the surrounding residues. In any case, all the features mentioned above make of the
E3/K3 tag a very powerful tool for those experiments that need a strong association of
two target proteins, yet avoiding the use of a bulky dimerization tag. Although other
coiled-coils have been used in protein purification [138, 139, 143, 161], we have chosen
the E3/K3 pair both because of its small size (21 aminoacids) and because its properties
were quite promising in a previous study [141]. Recently, it has also been used as a
fluorescent marker to study EGFR internalization [162]. The induced dimerization of
EGFR receptors has been tried before, but in different experimental setups. Split-
protein systems, such as split luciferase and split Venus have been used in cells to study
conformational changes and the association state of EGF receptors [76, 163]. The TEV
protease split system has also been used to monitor protein association states [164]. The
dimerization domains FRB and FKBP have also been used in EGF receptors with the
same purposes [163, 165–167]. However, these systems are not suitable for purification,
because they were designed to observe natural interactions between protein subunits,
not to maintain them. It is true that another coiled-coil pair, the GCN4, has been
used as a tool for the purification of VEGF receptor ectodomains [168] and in EGFR
kinase domain studies [63]. Although this protein is used as an archetypical coiled-coil
interaction in protein design experiments (for example [145]), it is based on the natural
activator GCN4. I wanted to have a completely synthetic pair in order to avoid any
interaction with cellular proteins. Besides, the GCN4 interaction is homomeric. In light
of the results, the E3/K3 pair can be used for the study of EGF receptor dimers, and
could be easily translated to other cellular receptor systems.
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5.2 Phosphorylation and activity of EGFR preformed
dimers in vivo and in vitro
I have shown that induced EGFR E3/K3 dimers are able to generate a proper down-
stream signal only upon ligand binding. The total levels of phosphotyrosine rise upon
ligand binding, just as expected. The fact that about 80% of the expressed EGFR
receptors exist in a dimeric form shows that the E3/K3 preformed dimers are not ac-
tivated before ligand binding. This has also been shown in the literature before [165].
Two canonical EGFR autophosphorylation sites, Y992 and Y845, were also assayed in
vivo. Y845 has recently been shown to be an autophosphorylation site of EGFR [153]
as well as in this study, although its phosphorylation is also dependent on Src [35].
No other autophosphorylation sites were analyzed because the constructs lack the C-
terminal tail, where the vast majority of autophosphorylation sites are clustered. The
analysis of Y845 and Y992, however, showed that the total amount of these two phos-
photyrosines remained almost constant after ligand binding. This fact can mean that,
either the EGFR preformed dimers are maximally phosphorylated at these two residues
before ligand binding, or that only a small portion of dimers are phosphorylated and no
further phosphorylation happens after ligand binding. The results in vitro show that,
starting from a non-phosphorylated kinase, the EGFR receptors are able to autophos-
phorylate and phosphorylate an exogenous substrate. For this reason, we think that
the EGFR receptors in vivo are maximally phosphorylated at these two residues before
ligand binding. The other possibility would imply that the kinases are not active, which
goes against the observations in vitro. But why are the kinases further phosphorylated
after ligand binding in vivo, while Y992 and Y845 are already phosphorylated? We
think that, before ligand binding, the kinases in a preformed dimer are interacting in
a way that avoids the exposure of certain surfaces to cellular proteins, hence inhibit-
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ing the phosphorylation of key tyrosine residues involved in signalling. Upon ligand
binding, the structural changes in the extracellular domains are transferred to the ki-
nase domains, which would expose both the already phosphorylated tyrosines and the
surfaces that were hidden before ligand binding. This would now allow the docking
of cellular proteins onto these sites and the phosphorylation of other tyrosine residues.
These results show that phosphorylation must be accompanied by a structural change
for signal transduction to occur. On the other hand, the phosphorylation state of Y845
doesn’t seem to be very important for EGFR signal transduction [35, 90]. In this sense,
EGFR is different to other protein tyrosine kinases, in which the phosphorylation of
the tyrosine at the activation loop is essential for their activity. I have also shown that
CHO-TetOn cells seem to have a higher background of phosphorylated Y845 and Y992.
Since the phosphorylation of these residues prior to ligand binding does not trigger a
downstream signal, we can conclude that both a structural change and phosphoryla-
tion are needed in order to activate a downstream pathway. It is also important to note
that basal phosphorylation of Y845 has been reported in the literature, and it does not
trigger a downstream signal, just as reported in this work [169].
5.3 Ectodomain asymmetry of preformed EGFR dimers
and curvilinear Scatchard plots
Curvilinear Scatchard plots of ligand binding to EGFR receptors were seen for the first
time almost three decades ago [104, 105]. How a single receptor with identical sequence
can generate high and low affinity sites for its ligand has remained unknown for a long
time. In this study, I have shown that the ectodomain architecture of preformed EGFR
dimers is far away from the symmetry that previous studies and mathematical models
have assumed [87, 112]. One of the ectodomains adopts a tethered conformation, albeit
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with a different angle between domain IV and the rest of the molecule, while the other
ectodomain is in an open conformation and probably has a high flexibility. This fact
points to the possibility that the two binding sites are not equivalent, since they are
structurally different, and could translate into the high and low affinity states of the
EGFR receptors. However, the amount of high-affinity sites is about 1% of the total
number of sites. If we took the structural model at its simplest, we would expect 50%
of the sites being high-affinity, and 50% of the sites being low affinity. This is very
far from the experimental observation, and hence a different mechanism must occur in
order to explain the high and low affinity sites. In recent studies [107, 170], the high and
low affinity sites have been explained as a result of negative cooperativity in preformed
dimers. Insulin receptors, related to EGF receptors, also show negative cooperativity
[117, 118]. Another fact that supports the negative cooperativity hypothesis is the
recent structural study on Drosophila EGF receptor [116]. This study shows that the
binding of one Spitz ligand to the predimerized EGF receptor provokes a conforma-
tional change in the second site, closing it and reducing its affinity for the ligand. The
difference between these studies and the present one is that the preformed, unliganded
dimers are assumed or observed to be structurally equivalent. The structure that I have
presented in this study reveals an unmistakable ectodomain asymmetry prior to ligand
binding. We have not proved if this structure presents any kind of negative cooperativ-
ity, but the fact that both ectodomains are interacting closely could point towards this
explanation. The negative cooperativity could arise from a structural change generated
by the interaction between the two ectodomains prior to ligand binding. Besides, a
one-site equation with Hill coefficient can be very nicely fitted to our data. When the
fits of a two-site and a one-site with Hill coefficient are compared, a two-site fitting is
preferred, but with P=0.02. If we decrease the threshold to P=0.01, then a one-site
with Hill coefficient fitting is preferred, with nH = 0.88 ± 0.02 (Figure 43).
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Figure 43: Comparison between two-site binding and one-site binding with
Hill coefficient. A) Left panel, two-site binding saturation curve (black line) fitted
to the experimental data (red dots). Right panel, Scatchard transformation. B) Left
panel, one-site binding saturation curve with Hill coefficient (black line, nH = 0.88 ±
0.02) fitted to the experimental data (red dots). Right panel, Scatchard transformation.
The fact that only 1% of the sites is able to bind ligand with high affinity could
be explained by the flexibility of the right ectodomain. This would scan different
conformations, of which only a reduced number corresponds to the high affinity state:
L-L
H-L,
where H is high affinity site and L, low affinity site.
In this sense, both ligand binding sites would represent a low affinity state, but one
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of them would be in a dynamic equilibrium because of the interaction with another
EGFR molecule and probably some intracellular components. In some configurations,
one of the low affinity states would change and form a high affinity site. From our model,
we think that the right ectodomain (depicted in orange in the figures) is the one that
undergoes these changes, since it seems to be more flexible than the left one (in blue).
The right ectodomain seems to adopt the dynamic configuration of a monomeric EGF
receptor seen in previous studies [159] and monomeric receptors are thought to have high
affinity binding in vivo [107]. On the other hand, the left ectodomain presents a tethered
configuration, more similar to the one seen in crystal structures [24–26]. This fact could
mean that the right ectodomain hinders the inherent flexibility of the left one, poising
it in a low affinity state. The fact that experiments with isolated ectodomains have
failed to show two binding sites highlights the importance of describing the interactions
that take place between two EGFR monomers in terms of a full-length molecule (or at
least near full-length, like the one used in this study).
However, we cannot rule out the possibility that the high and low affinity states
are due to slight structural changes that are too subtle to be seen at 33 A˚ resolution,
in which case any of the ectodomains could serve as a high affinity site. Having two
structurally different sites suggests also some kind of hierarchy in ligand binding, which
could have consequences for downstream signalling, as will be commented on later.
Other studies have shown that the intracellular domains, particularly the juxtamem-
brane, have a role in the maintenance of the high-affinity state [95, 108]. Unfortunately,
the resolution achieved doesn’t allow us to infer any structural conformations of this
part of the molecule. However, the purified EGFR dimers are lacking a membranous
environment, which makes their kinases active even in the absence of ligand. The jux-
tamembrane region is known to be also involved in regulating EGFR kinase activity
[63, 96, 97]. It is very possible that the juxtamembrane region of the purified EGFR
92
5. DISCUSSION
receptors is not in its native configuration. The kinase domains are also known to be
involved in the establishment of preformed EGF receptor dimers [149], and in our ex-
perimental system we know that the kinase domains are active even in the absence of
ligand after solubilisation. This implies that the kinase domains may not be in their
normal configuration, which could also have an effect on the way the ectodomains are
interacting. All these effects could make the high-affinity binding state unstable and
hence decrease the observed high affinity sites to about 1%.
Why is one of the ectodomains tethered while the other seems to be in an extended
conformation, or even scanning different configurations? What are the molecular mech-
anisms that allow this to happen? The tethered conformation involves a dimerization
loop in domain II that interacts with domain IV. However, in this structure I have
shown that domain IV of the tethered ectodomain forms a different angle with the rest
of the molecule, and the dimerization loop is too far away to interact with domain
IV. Nevertheless, this ectodomain seems to be constrained to this tethered conforma-
tion. On the other hand, domain IV of both molecules seems to be interacting closely,
especially at the C-terminal stretch. We think that the dimerization loop of the teth-
ered ectodomain is no longer interacting with domain IV of the same molecule, but
with a part of the extended ectodomain. Unfortunately, at this resolution we can-
not unequivocally identify which region(s) of the extended ectodomain are involved.
However, mutation studies have shown that mutation of Y246, a residue present in
the dimerization loop, abolishes dimerization of EGF receptors, and most interestingly,
the mutated receptor presents only low affinity binding [86, 107]. A recent study has
identified a region in the tethering arm (residues 571-593, at the C-terminal portion
of domain IV), that when deleted abolishes any kind of cooperativity, and hence the
receptors have only one affinity state [170]. These results support our hypothesis of an
involvement of the tethering arm in the maintenance of ectodomain asymmetry, and
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hence, the high affinity state. From our 3D reconstruction, domain IV seems to form an
angle with the transmembrane region, and not just a simple linear continuation of the
polypeptide chain. This would imply that the hinge domain between domain IV and
transmembrane is very flexible, which would also support our idea that domain IV of
the right, extended ectodomain is able to move back and forth, changing the distance
between domains I and III and generating a high affinity site. In a recent publication
[51] this has been shown to be the case. The 7 aminoacids connecting domain IV with
the transmembrane region seem to be extremely flexible. In some molecular dynamics
studies [171, 172] the EGFR dimers are not standing proud off the membrane, but lying
on it, which would also imply a high flexibility in this region. These MD simulations
are backed up by some in vivo studies [130]. Again, it seems to be very important that
the interaction between two EGFR monomers is described with full-length molecules,
as it seems very probable that this back- and forth movement of the right ectodomain
is triggered by the tethered, left molecule. That would also explain why we do not see
the enantiomer (left ectodomain extended, right ectodomain tethered). There seems to
be a very well defined interaction surface between the two ectodomains that involves
different sides of the EGFR molecules, hence yielding the asymmetric structure I have
presented. In order to prove these hypotheses, the above mentioned mutants should be
structurally and biochemically characterized with the E3/K3 system, and an increase
in resolution would allow a better definition of the interaction sites between the two
ectodomains.
94
5. DISCUSSION
5.4 Biological implications of ectodomain asymme-
try in EGFR preformed dimers
The fact that preformed EGF receptors present ectodomain asymmetry has a number
of different implications, the most obvious being a hierarchy in ligand binding. This
would imply that one of the ectodomains (high-affinity) binds ligand before the other
one (low affinity), and hence transmits this change to its kinase domain. Following this
line of thinking, there is the intriguing possibility that single-liganded dimers are able
to signal. In this case, one of the kinases would phosphorylate its partner, showing
a different interface and phosphotyrosine pattern than the double-liganded dimer, or
maybe generating a different order of tyrosine phosphorylation. This idea has been
commented by [107] and this work shows additional pieces of evidence supporting it. In
this way, single-liganded dimers would mediate different responses than double-liganded
dimers. The cell could respond differently to low and high concentrations of the same
ligand, without the necessity of generating a different receptor. By controlling where the
receptors are located, and hence displacing the equilibrium towards preformed dimers of
EGFR, the cell could also respond asymmetrically to ligand addition. These two ideas
have been studied in two recent publications [111, 173], in which they show that EGF
receptors generate different downstream signals depending on the ligand concentration,
and that EGF receptors can be located in membrane in an asymmetric manner.
I propose an activation model that implies the association of two unliganded EGFR
monomers, mainly via their ectodomains and regulated by their kinase and juxtamem-
brane regions. The association of the ectodomains is asymmetric, and generates two
ligand-binding sites that are not equivalent, thus making possible the existence of both
high and low-affinity sites within an EGFR dimer. This would allow cells to respond
differently to diverse concentrations of ligand (Figure 44).
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Figure 44: Proposed activation pathway for the EGF receptor. Top panel, clas-
sic, sequential activation model for EGF receptors. They exist in a tethered, monomeric
state and ligand binds sequentially to generate an active, doubly liganded dimer. Bot-
tom panel, activation pathway involving preformed EGF receptor dimers. In the ma-
jority of configurations, the preformed EGF receptor dimer has low affinity sites, but
one of the ectodomains is able to scan different conformations, of which one corresponds
to the high affinity state. The other ectodomain retains low affinity, and represents the
second binding event to generate a doubly liganded dimer.
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EGFR is involved in many cellular pathways and its abnormal behaviour can cause
a plethora of illnesses, as has been commented on before. It is well true that we have
a lot of information regarding the mode of action, activation and regulation of ErbB
receptors, but we are lacking a complete picture of these processes. The first step in
ErbB receptor activation is ligand binding, a seemingly simple mechanism that has
proved to be very difficult to untangle. With this work I have added a new point of
view that hopefully will serve as the basis for future work, not only no the fields of basic
research, but also applied to the development of new molecules and therapies that could
serve as blockers for aberrant EGFR-mediated signalling.
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6Materials and Methods
6.1 Materials
6.1.1 Constructs used in the characterization of the E3/K3
interaction
- pET21a-Stag-Venus-K3-KLAATLE-His: bacterial expression of N-terminally S-
tagged Venus followed by the K3 peptide. The K3 sequence is followed by the endoge-
nous pET21 linker before the hexahistidine tag (KLAATLE).
- pET21a-Stag-Venus-K3-pG-His: bacterial expression of N-terminally S-tagged
Venus followed by the K3 peptide. A polyglycine linker (GGSG) was introduced be-
tween the K3 and the his tag, the final sequence being GGSGLE.
- pET21a-Stag-Venus-TEV-K3-pG-His: bacterial expression of N-terminally S-
tagged Venus followed by the K3 peptide. A TEV cleavage site (ENLYFQG) was intro-
duced after the Venus coding sequence and followed by a polyglycine linker (GGSG),
the K3 sequence, a polyglycine linker (GGSG) and a hexahistidine tag.
- pET21a-Stag-Venus-TEV-K3-PPG-His: variation of the pET21a-Stag-Venus-
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TEV-K3-pG-His construct including a diproline motif (PP) after the K3 sequence and
before the polyglycine linker (final sequence is PPGSGLE).
- pET21a-ECFP-E3-pG-Strp: bacterial expression of ECFP followed by the E3 pep-
tide. A polyglycine linker (GGSG) was introduced between the E3 and the Strep tag
II (WSHPQFEK). A stop codon immediately follows the Strep tag.
- pET21a-ECFP-TEV-E3-pG-Strp: variation of the pET21a-ECFP-E3-pG-Strp
construct in which a TEV cleavage site (ENLYFQG) was introduced after the ECFP
coding sequence, followed by a polyglycine linker (GGSG), the E3 sequence, a polyg-
lycine linker (GGSG) and a Strep tag II.
6.1.2 Constructs used for the purification and characterization
of the ErbB receptor pairs
- pBI-1delta-E3/1delta-K3: co-expression of EGFR-delta998-TEV-K3-pG-His and
EGFR-delta998-TEV-E3-pG-Strp from a single, bidirectional promoter in CHO-K1
TetOn cells (Clontech). The parent plasmid was from Addgene (Plasmid 16623: pBI-
GFP).
- pBI-1FL: expression of full-length EGFR-TEV-Strep from a single promoter in CHO-
K1 TetOn cells (Clontech).
- pBI-1delta-E3/2-delta-K3: co-expression of EGFR-delta998-TEV-E3-pG-Strp and
ErbB2-delta1007-TEV-K3-pG-His from a single, bidirectional promoter in CHO-K1
TetOn cells (Clontech). The polyglycine arm variant includes a 10-residue linker
(GGGSG)2 after the TEV sequence.
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6.2 Methods
6.2.1 Cloning of the Venus/ECFP E3/K3 constructs
The ORFs for Venus and ECFP were amplified from the plasmids pPWV and pPWC,
a kind gift from Leonie Ringrose Group (IMBA, Vienna), and cloned between the
NdeI and HindIII sites of a pET-21a vector. In the case of ECFP, a Strep-tag II
(WSHPQFEK) preceded by a polyglycine (pG) linker and followed by a stop codon was
added just before the vector’s his tag sequence. An S-tag (KETAAAKFERQHMDS)
coding sequence was added at the 5’ end of Venus, in order to increase its molecular
weight and differentiate it from ECFP in subsequent analyses. Two complementary
oligos coding for K3 and E3 peptides, preceded by a polyglycine linker (GGSG, in
which the underlined residues are the translation of a BamHI site) and including the
overhangs for Bsp1407I and HindIII, were annealed and cloned into these sites of the
pET-21-S-Tag-Venus and pET-21- ECFP, respectively. These vectors were named pET-
21-SVenus-K3-KLAATLE-His and pET-21-ECFP-E3-Strp. KLAATLE is the pET-21a
sequence between the HindIII site and the His tag. The K3-polyglycine variant was
generated as above, but with the polyglycine coding sequence just after the K3 sequence
and inserted between the Bsp1407I and XhoI sites of pET-21S-Tag-Venus. The linker
between the K3 peptide and the his tag in this case is GGSGLE. The TEV variants
were generated by annealing two complementary oligos coding for the TEV cleavage
site (ENLYFQG) and cloning them into the Bsp1407I and BamHI sites of pET-21S-
Tag-Venus-K3-pG-His and pET- 21-ECFP-E3-Strp, yielding pET-21-SVenus-TEV-K3-
pG-his and ECFP-TEV-E3-Strp.
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6.2.2 Expression, purification and TEV cleavage of E3/K3–
tagged ECFP /Venus
The different constructs were transformed into BL21 Rosetta and grown in LB plates
supplemented with ampicillin, single colonies picked and transferred to 1 L flasks in the
presence of ampicillin and chloramphenicol (100 µg/mL and 25 µg/mL, respectively).
Expression was induced overnight at OD 600 = 0.7 with a final concentration of 1
mM IPTG, at 250C. Cells were then harvested at 6000xg, 15 minutes and the pellet
resuspended in 70 mL lysis buffer (Tris 20 mM, NaCl 150 mM, imidazole 10 mM, pH
7.5). The suspension was sonicated 3 times, 1 minute and centrifuged at 20.000xg, 25
minutes, 40C. The supernatant was then filtered with a 0.25 µ pore size membrane and
applied to either a HisTrap 1mL or a StrepTrap 5mL (GE Healthcare) using an A¨KTA
HPLC chromatography system. For HisTrap purification, the column was washed with
lysis buffer plus 20 mM imidazole and eluted in lysis buffer 300 mM imidazole. For
StrepTrap purification, the column was washed with lysis buffer and eluted with lysis
buffer plus 2.5 mM D-desthiobiotin. Eluted fractions were pooled and its concentration
measured with the Bradford method (20 µL sample in 1 mL Bradford reagent) per
triplicate. For the tandem affinity purification, the ECFP-TEV-E3-Strp lysate was
treated with 500 µL NiNTA magnetic beads (Qiagen NiNTA Superflow) in order to
clear the sample from any proteins whose synthesis may have not finalized after the stop
codon and continued through the his tag. Both SVenus-TEV-K3-pG-his and ECFP-
TEV-E3-Strp lysates were mixed and a sequential affinity purification (StrepTrap after
HisTrap) carried out as described above. The purity of the samples was assayed by
SDS-PAGE and Coomassie staining. For the gel filtration assays, purified samples were
brought to the desired concentration in 250 µL lysis buffer and loaded onto a Superdex
200 10/300 GL column (GE Healthcare, bead volume 24 mL) at a flow rate of 0.6 mL/
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min, previously equilibrated with 35 mL lysis buffer. Eluted fractions were collected
in 250 µL aliquots, tested for fluorescence levels and the concentration of the highest
peak measured with a Bradford assay (20 µL sample in 1 mL Bradford reagent). The
purity of the samples was assayed by SDS-PAGE and Coomassie staining. For the
TEV cleavage, purified, his-tagged TEV (a kind gift from Westermann group, IMP)
was added to the purified Venus and ECFP samples, and left overnight at 4o in lysis
buffer plus 1 mM DTT. On the next day, samples were loaded onto a NiNTA column
and the flowthrough collected.
6.2.3 Gel filtration standard curve
All calculated molecular weights, in both the Venus/ECFP as well as in the EGFR
experiments, were extrapolated from a standard curve of a mixture of gel filtration
molecular weight markers (BioRad). 100 µL of these mixture were brought to a volume
of 250 µL in PBS buffer and loaded onto a Superdex200 column (GE Healtcare) con-
nected to an A¨KTA HPLC system. The markers used and the observed elution volumes
are:
- Thyroglubulin: 670 kDa, 9.30 mL.
- Gamma–globulin: 158 kDa, 12.81 mL.
- Ovalbumin: 44 kDa, 15.37 mL.
- Myoglobin: 17 kDa, 17.33 mL.
The molecular weight is given by the equation Log(MW,Da) = −0.2014x+ 4.7379,
where x is the observed elution volume of a sample. R2=0.99829.
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6.2.4 Fluorescence measurements, FRET efficiency and dis-
tance estimation
A final concentration of 2 µM for each species was used (SVenus-TEV-K3-pG-His only,
ECFP-TEV-E3-Strp only, manually mixed equimolar amounts of the TEV constructs
and tandem affinity purified heterodimer). The samples were diluted to the desired
concentration in a final volume of 200 µL lysis buffer and their fluorescence measured
in a Tecan GeniosPro fluorescence reader (manual gain 25, four measurements per well).
Samples were assayed per triplicate. In the case of FRET efficiency buffer screening, the
samples were dialysed against the desired buffer before mixing (except for the Triton
X100 buffer, in which the samples were brought to a final detergent concentration of
1% by mixing them with a 2X concentrated buffer). Venus channel, excitation 505
nm emission 535 nm, FRET channel, excitation 420 nm/emission 535 nm, and ECFP
channel, excitation 420 nm/emission 465 nm. The error bars show the standard error
(σ/n) of the three measurements. This value was used for the calculation of FRET
efficiency and distance estimation errors (error propagation). The FRET efficiency (E)
was calculated with the fluorescence reduction of the donor (ECFP) in the presence of
the acceptor (Venus), according to the following relationship:
E = 1− Rmix
R
Equation 1
[174], where R is the fluorescence ratio of an ECFP-only sample over a Venus-
only sample , Rmix is the fluorescence ratio of ECFP over Venus when both proteins are
mixed, subtracting the expected spill over of each protein in other fluorescence channels
when measured alone, as follows:
Rmix =
ECFPChannelmixed−ECFPChannelVenus
V enusChannelmixed−V enusChannelECFP
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And once the efficiency is known, the distance can be calculated with the following
equivalence:
d(A˚) = 50× 6
√
1
E
− 1 Equation 2
50 A˚ is the Fo¨rster distance for the pair ECFP/Venus.
http://www.microscopyu.com/tutorials/java/fluorescence/fpfret/index.html
6.2.5 Isothermal Titration Calorimetry
A VP–ITC Microcalorimeter (MicroCal, LLC) was used. ECFP-TEV-E3-Strp was
brought to a final concentration of 100 µM in the syringe and SVenus-TEV-K3-pG-His
to 10 µM in the chamber, both in lysis buffer. 30 injections of 10 µL each, with a delay
of 1 minute between injections, were carried out at a temperature of 250C. The results
were analyzed and plotted using MicroCal Origin software.
6.2.6 Mammalian cell culture
Adherent cells were maintained in complete-DMEM (high glucose) medium from IMBA/
IMP media kitchen, supplemented with 7% FCS (Sigma Aldrich), 2 mM glutamine
(Sigma Aldrich) and 1X non-essential aminoacids (Sigma Aldrich), in a humid incu-
bator at 370C and 5% CO2. For the maintenance of CHO-K1 TetOn and its derived
stable cell lines, a final concentration of 150 µg/mL G418 was added to the medium. For
induction of CHO-K1 TetOn, complete-DMEM was exchanged for serum free-DMEM
plus 1µg/mL doxycycline, having the same formulation as above but containing no
FCS.
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6.2.7 Cloning of EGFR and ErbB2 E3/K3 constructs
EGFR∆998 and ErbB2∆1007 were amplified from the parental plasmids pCMV-HER1
and pMMTV-HER2, a kind gift from Erwin Wagner’s lab, IMP. The plasmid back-
bone was pBI-GFP (Addgene plasmid number 16623). All forward oligos contained a
mammalian ribosome binding site just before the ATG start codon (GCCACC–ATG).
- Generation of pBI-EGFR∆998–E3Strp/EGFR∆998–K3pGStrp: pBI-GFP
was cut with NotI and SalI. The coding sequence for EGFR∆998 was amplified from
pCMV-HER1 including both restriction sites and adding a SpeI site just before the SalI
site. This was cloned into pBI-GFP, generating pBI–EGFR∆998–SpeI–SalI/GFP. This
plasmid was cut with NheI and Bsp1407I, removing the GFP sequence from the parental
plasmid. The coding sequence for EGFR∆998 was amplified from pCMV-HER1 in-
cluding both restriction sites NheI and Bsp1407I and adding an AflII site before the
Bsp1407I site. The produced plasmid was pBI–EGFR∆998–SpeI–SalI/EGFR∆998–
AflII–Bsp1407I. Two complementary oligos coding for TEV-E3-Strp-Stop were an-
nealed, including the overhangs for SpeI and SalI, and cloned into pBI–EGFR∆998–
SpeI–SalI/EGFR∆998–AflII–Bsp1407I. The generated plasmid was pBI–EGFR∆998–
TEV-E3-StrpI/EGFR∆998–AflII–Bsp1407I. This was finally digested, and two comple-
mentary oligos coding for TEV-K3-pG-His-Stop were annealed, including the overhangs
for AflII and Bsp1407I, and cloned into the plasmid above. The final plasmid was pBI–
EGFR∆998–TEV-E3-StrpI/EGFR∆998–TEV-K3-pG-His.
- Generation of pBI–EGFR∆998–TEV-E3-StrpI/ErbB2∆998–TEV-(polyGly)–
K3-pG-His: The same protocol as above was followed, but exchanging the EGFR∆998–
AflII–Bsp1407I sequence for an ErbB2∆1007–AflII–Bsp1407I. This sequence was am-
plified from pMMTV-HER2. For the polyglycine constructs, a sequence coding for
(GGGSG)2 was added just before the K3 coding sequence. The final plasmid was then
pBI–EGFR∆998–TEV-E3-StrpI/ErbB2∆998–TEV-(polyGly)–K3-pG-His.
106
6. MATERIALS AND METHODS
- Generation of pBI–EGFR–Full Length–Strp/GFP: EGFR-Full Length was am-
plified from pCMV-HER1 including the NotI and SalI restriction sites and a C-terminal
Strp tag followed by a stop codon, and cloned into pBI–GFP. The plasmid generated
was pBI–EGFR–Full Length–Strp/GFP.
6.2.8 Preliminary purification tests of EGFR constructs
Lipofectamine 2000 (Invitrogen) was used to transfect 80-90% confluent CHO-K1 TetOn
cells according to the manufacturer’s instructions. 3,5 µg of plasmid (pBI-1deltaE3/
1deltaK3 or pBI-1FLE3/1FLK3) were mixed with 8,5 µL of Lipofectamine 2000 reagent.
This mix was added to CHO-K1 TetOn cells and removed after 5-6 hours incubation at
370C. The medium was then exchanged to serum free-DMEM plus 1µg/mL doxycycline.
After 18-21 hours of induction, cells were washed 3X with ice-cold PBS and solubilised
in Solubilisation Buffer (Tris 20 mM, NaCl 150 mM, Triton X100 0.2% v/v, EDTA
1mM, protease inhibitors (Roche Complete EDTA-free), 0.5 mM beta-mercaptoethanol
(2-ME)) for one hour on ice. Lysates were cleared by centrifugation at 20000g, 30
minutes at 40C. The supernatant was then applied to a Strep-Tactin spin column (IBA
Germany) and the purification was done following the manufacturer’s instructions, but
supplementing the kit’s wash and elution buffers with 0.1% Triton X100. The eluted
fraction from the Strep-Tactin spin columns was loaded onto a NiNTA-agarose spin
column (Qiagen), washed with wash buffer supplemented with 0.1% Triton X100 and
eluted in Tris 20 mM, NaCl 150 mM, Triton X100 0.1%, 300 mM imidazole. All buffers
contained protease inhibitors. The order of tandem affinity purification can be reversed
in some experiments, and it will be stated so in the text. Samples were analysed by
western blot. In the case of EGFR/ErbB2 heterodimer tests, geldanamycin was added
to the solubilization buffer at a final concentration of 10µM at 45 minutes after initiating
the solubilization, and incubated for further 15 minutes on ice.
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6.2.9 Generation of CHO-K1 TetOn stable cell lines
A 10-cm Petri dish with 80-90% confluent CHO-K1 TetOn cells was used. pBI-1deltaE3/
1deltaK3 and pTK-Hyg (carrying a hygromycin resistance gene) were transfected as
described above (molar ratio 10:1), substituting the serum free-DMEM with complete-
DMEM. After 24 hours, cells were trypsinized and split 1:10 in complete-DMEM con-
taining 150 µg/mL G418 and 250 µg/mL hygromycin (Invitrogen). When massive cell
death occurred (about 5 days later), the plates were washed with PBS and the medium
exchanged to new complete-DMEM supplemented with 150 µg/mL of both G418 and
hygromycin. Cells were allowed to grow to confluence and then a serial dilution was
performed, in order to achieve about 2-4 cells/mL. 250 µL of this dilution were seeded
into 96-well plates and single colonies allowed to grow. These colonies were then trans-
ferred to 6-well plates, per duplicate. One of the duplicates was induced in serum
free-DMEM with 1µg/mL doxycycline for 18-21 hours, lysed in SDS-PAGE sample
buffer and assayed for expression by western blot using anti-hexahistidine (Qiagen) and
anti-NWSHPQFEK (Genscript) antibodies. Positive colonies for both antibodies were
allowed to grow and frozen in complete-DMEM containing 10% DMSO and no selection
drugs. These cell lines were labelled CHOK1-TetOn-1deltaE3/1deltaK3.
6.2.10 Large scale expression and purification of EGFR con-
structs from CHO-K1 TetOn cells
CHOK1-TetOn-1deltaE3/1deltaK3 were grown in 175 or 500 cm2 plates to 80-90%
confluence in complete-DMEM containing 150µg/mL G418 and 250 µg/mL hygromycin.
A typical expression assay consists of about 25-30 x 175 cm2 plates. Cells were washed
2X with PBS to remove all traces of serum and induced in serum free-DMEM containing
no selection drugs and 1µg/mL doxycycline for 18-21 hours. Plates were put on ice,
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washed 3X with ice-cold PBS and carefully scraped off the plate in PBS containing 1
mM EDTA and protease inhibitors (Roche Complete, 3 tablets/250 mL), using 5 mL per
plate. Cells were pelleted at 800g, 6 minutes, 40C. The PBS was removed and the pellet
immediately frozen at -800C. Pellets from 25-30 x 175 cm2 plates were not allowed to
thaw and immediately solubilised in ice-cold Solubilisation Buffer (Tris 20 mM, NaCl
150 mM, Triton X100 0.2% v/v, EDTA 1mM, protease inhibitors (Roche Complete
EDTA-free), 4 tablets per 80 mL and 0.5 mM 2-ME), for 45 minutes on ice. Lysates
were cleared at 50000g, 40C, 30 minutes, and the supernatant filtered with a 0.25 µ
pore size membrane. This supernatant was applied to a StrepTactin-5mL column (GE
Healthcare) in an A¨KTA system. The column was washed with 60 mL of Wash Buffer
(Tris 20 mM, NaCl 150 mM, Triton X100 0.1%, 2-ME 0.5 mM, protease inhibitors)
and eluted in Wash Buffer plus 2.5 mM desthiobiotin (Sigma) and protease inhibitors.
The eluted fractions were pooled and applied to a 1mL NiNTA-agarose column (GE
Healthcare) in an A¨KTA system, washed with 10 mL Wash Buffer and eluted in Wash
Buffer plus 300 mM low-absorbance imidazole plus protease inhibitors. Peak fractions
were confirmed with a Bradford assay, pooled and applied onto a Superdex-200 column
(GE Healthcare). The gel filtration run was performed in DDM-150 buffer (20 mM
Tris, 150 mM NaCl, 0.4 mM dodecylmaltopyranoside, (DDM)).
6.2.11 Fluorescence microscopy of in vivo ligand binding
Stable CHO-TetOn cell lines expressing EGFR∆998 E3/K3 dimers were grown to 80-
90% confluence on glass coverslips and expression induced for 22 hours with 1 µg/mL
doxycycline in serum-free medium. Cells were then washed 2X with ice-cold PBS and
treated with 100 ng/mL EGF-Rhodamine (Invitrogen) in serum-free medium plus 0.1%
BSA on ice for 15 minutes. After this, cells were washed twice with ice-cold PBS and
either fixed directly with methanol or brought to 370 C for 10 minutes to induce receptor
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intake before fixation. Mounting medium contained DAPI (Vectashield). Cells were
then imaged in a LSM700 confocal microscope (Zeiss) under laser excitation 405 nm
(DAPI) and 555 nm (Rhodamine) and emission filters 490 nm and 560 nm, respectively.
6.2.12 Kinase assays of purified EGFR dimers
Western-blot analysis: EGFR∆998 E3/K3 dimers were purified as in 6.2.10 and loaded
onto a Superdex200 column. Fractions containing the dimers were split into two, and
treated either with 20 µM ATP only or with 20 µM EGF on ice for 20 minutes and 20
µM ATP in buffer supplemented with 1mM Na3VO4, and the phosphorylation state was
analyzed by western blot (total phosphotyrosine, pY845, pY992, his- and strep-tags).
Colorimetric analysis: Gel filtration fractions were split into two, and loaded onto a
well of a 96-well plate coated with a synthetic poly-(Glu-Tyr) substrate, with a wide
specificity spectrum (Takara). Wells were treated with or without 20 µM EGF on ice for
20 minutes, and the reaction was started by adding 20 µM ATP in buffer supplemented
with 1mM Na3VO4. The detection of the phosphorylated substrate was done follow-
ing the addition of an anti-phosphotyrosine antibody and colorimetric quantification
(ELISA).
6.2.13 Activation and signalling of EGFR constructs in vivo
Cells were seeded in 6-well plates and left to reach 80-90% confluence. CHO TetOn
cells stably expressing EGFR∆998 E3/K3 dimers and unmodified CHO TetOn cells
were washed twice with PBS and expression induced for 22h in DMEM serum-free
medium containing 1 µg/mL doxycycline. A431 cells were starved in DMEM serum-
free medium for the same period of time. Cells were then treated with or without 100
ng/mL EGF in DMEM serum-free plus 0.1% BSA for 8 minutes at 370C. Wells were
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immediately washed twice with ice cold PBS and collected in 700 µL 2.5X Laemli buffer
supplemented with 1mM Na3VO4, boiled for 5 minutes and analyzed by western blot.
6.2.14 Ligand saturation assays of purified EGFR dimers
Fractions containing purified EGFR∆998 unliganded dimers were pooled and bound to
black nickel-coated 96 well plates per triplicate. Europium-EGF (Eu-EGF, PerkinElmer)
was added to the wells at concentrations ranging from 0.01 to 70 nM. Non-specific bind-
ing was calculated per duplicate by adding 3 µM unlabeled EGF at each concentration
of Eu-EGF. Samples were left at room temperature for two hours. After washing and
adding enhancement solution (HVD Life Science Vertriebs) according to the manufac-
turer’s instructions, fluorescence levels of bound ligand were measured by TRF (time
resolved fluorescence) in a TECAN GeniosPro fluorometer. Excitation wavelength 340
nm, emission wavelength 612 nm, manual gain 70, integration time 700 µs, lag time
175 µs, number of reads 10, multiple reads per well 3x3, square, mirror dichroic 3. A
standard curve was calculated in the same way by adding known amounts of Eu-EGF
per duplicate to wells containing enhancement solution only. The free ligand concentra-
tions were calculated by subtracting the bound ligand from the added concentrations,
plotted and analysed with Graph Pad Prism. The tables and figures below show the
actual values obtained in the experiments.
111
6. MATERIALS AND METHODS
Added nM Free nM Specific binding nM Unspecific binding nM
Average SE Average SE Average SE
0.01 9.575E-3 3.464E-05 4.247E-4 3.464E-05 1.990E-05 -
0.02 1.910E-2 7.731E-05 8.959E-4 7.732E-05 1.991E-05 -
0.04 3.826E-2 2.096E-4 1.740E-3 2.101E-4 2.488E-05 1.493E-05
0.07 6.635E-2 3.521E-4 3.653E-3 3.520E-4 8.959E-05 -
0.1 9.540E-2 3.694E-4 4.599E-3 3.696E-4 2.190E-4 9.953E-06
0.2 0.193 9.09465E-4 7.064316E-3 9.26948E-4 5.77354E-4 1.79179E-4
0.4 0.38698112 1.443946E-3 1.301888E-2 1.446423E-3 7.61506E-4 8.46085E-05
0.7 0.681551096 1.820102E-3 1.8448904E-2 1.833225E-3 1.552887E-3 2.18957E-4
1 0.975120423 1.889994E-3 2.4879577E-2 1.890649E-3 2.070492E-3 4.97671E-05
2 1.953760258 4.674579E-3 4.6239742E-2 4.683795E-3 4.75321-3 2.93675E-4
4 3.907073702 7.10491E-3 9.2926298E-2 7.10491E-3 8.978976E-3 -
7 6.838420235 1.3050545E-2 0.161579765 1.3050545E-2 1.765932E-2 -
10 9.849497701 9.16129E-3 0.150502299 9.16129E-3 2.4000478E-2 -
20 19.66300782 2.8683376E-2 0.336992176 2.887428E-2 4.9623126E-2 3.314818E-3
40 39.59463462 3.5228786E-2 0.405365377 3.8543801E-2 8.2581825E-2 1.5638326E-2
70 69.51823598 3.7375979E-2 0.481764021 3.7386395 E-2 0.125379263 8.82458E-4
Table 6.1: Ligand saturation curve data.
Added nM Fluorescence Blank corrected
0 0.66667 0
0.0005 6.611 5.944
0.001 12.888 12.222
0.005 63.333 62.667
0.01 119.44 118.773
0.05 528 527.333
0.1 1177.4 1176.733
0.5 5329 5328.333
1 11284 11283.333
Figure 45: Standard curve for TRF.
6.2.15 Negative staining of purified EGFR dimers
For negative staining, fractions from purified 1deltaE3/1deltaK3 subjected to size ex-
clusion chromatography were used (fraction C4 of a normal run). Carbon-coated grids
were glow-discharged for 60 sec and a 5 µL sample was allowed to settle for 30-180
seconds, depending on protein concentration. The drop was blotted from a side and
the grid was washed 3 x 5µL water plus a final wash of 5 µL water for about 10 sec.
The water droplet was blotted from a side and the grid was quickly washed with 5 µL
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of stain (Nanovan; 0.75% uranyl formate; or 0.5% uranyl formate, depending on the
experiment). Finally, a 5µL droplet of stain was added to the grid for 30 seconds and
excess stain removed by blotting from a side. Grids were allowed to air-dry and either
used immediately or stored in a dehumidified vacuum chamber.
6.2.16 Image acquisition and processing
Negative-stain EM data was collected in an FEI Tecnai Polara at 300kV on a Gatan
Ultrascan 4000 UHS CCD (4k x 4k, pixel size of 15 micron) using the Leginon software
package for automated acquisition [175]. The final pixel size was 2.08 A˚ (71,949-fold
magnification), with the defocus ranging from -1.5µm to -4.5µm. The electron dose
used was between 40 to 60 electrons per A˚2 [176]. The mean defocus value of the image
was estimated by CTFFIND3 and corrected by phase-flipping with IMAGIC-5 (Image
Science Software GmbH, Germany). Particles were picked manually by using e2boxer
from the EMAN2 package [177]. First, an unbiased multi-reference 2D alignment was
performed by XMIPP using a maximum-likelihood target function [157, 158, 178]. The
resulting 2D classes (only ignoring classes most likely representing junk) were used
as initial references for several cycles of alignment-by-classification in IMAGIC-5 until
convergence was reached. No particles were removed from the dataset in the process.
6.2.17 3D model generation and refinement
A rough initial 3D model was generated in UCSF Chimera [179] from available EGFR
crystal structures. Selected forward projections of this model were matched to selected
2D classes of the particle by visual inspection, in order to obtain initial Euler an-
gles, in IMAGIC-5. A first generated 3D model was reprojected, and gradually more
classes were carefully included after visual inspection to improve the model. After a
113
6. MATERIALS AND METHODS
few rounds of supervised projection matching of 2D classes, several more rounds of un-
supervised projection matching of single particles were performed to refine the model.
Datasets were also split in half in order to calculate the Fourier shell correlation (FSC).
Furthermore, in order to analyse heterogeneity in the dataset, maximum likelihood
3D-refinement in XMIPP was performed [160].
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